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Locoregional treatment is the specific delivery of therapeutics to their desired sites of action 
with minimized systemic adverse effects. In this approach, drug is administered through 
topical instillation, inhalation, intra-lesional or intra-arterial injection. Decades of experience 
in locoregional treatment have delivered meaningful benefits to patients with localized 
diseases (e.g., osteoarthritis, ocular disorders and liver cancers). However, improvements are 
required for this type of treatment to be more effective. For transarterial chemoembolization 
(TACE) therapy of hepatocellular carcinoma (HCC), the most current approaches do not 
allow repeat treatment as the drug delivery vehicle is not degradable. In addition, image 
contrast agents for visualization are administered separately, leading to uncertainty of the 
drug location.   
In this thesis, the concept of a multifunctional ‘nano-on-micro’ delivery system was explored 
for enhanced TACE therapy. Magnetic hydrogels composed of poly(vinyl alcohol) (PVA) 
and iron oxide nanoparticles (IONPs) were prepared and shaped into microparticles using 
microfluidics. This system was able to deliver the anti-cancer drug, doxorubicin (DOX), with 
co-localized IONPs as a contrast agent to visualize drug location. Degradability of the PVA 
hydrogel carrier allows for repeat treatment. To enhance drug loading, we explored the use of 
silica nanoparticles (SiNPs) as an effective drug carrier. Loading was investigated using 
lysozyme as a model protein and applied to N-94, a therapeutic peptide for dry eye treatment. 
The results demonstrated SiNPs system could provide controlled drug release that is also 
degradable under simulated physiological conditions. Building on these results, silica (SiO2) 
was introduced to prepare PVA-SiO2-IONP microparticles. In addition to all the positive 
attributes of the original system, the PVA-SiO2-IONP microbeads have increased drug 
loading and tunable release profile.  
The concept of a multifunctional ‘nano-on-micro’ delivery system demonstrated for TACE 
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Summary for Lay Audience 
Locoregional therapy is a treatment strategy where therapeutics are delivered to sites of the 
diseases via topical instillation, inhalation or injection. This approach can potentially 
minimize the involvements of invasive surgery and systemic side effects. Transarterial 
chemoembolization (TACE) is a locoregional therapy that is used in the treatment of 
hepatocellular carcinoma (HCC), which is commonly known as liver cancer. Microbeads are 
used to block tumor blood vessels and to deliver therapeutic drugs to the tumor site.  Most of 
the beads currently used cannot be removed after the anti-cancer drug is delivered, so repeat 
treatment would not be possible. Also, to determine the location of the beads, imaging 
contrast agents have to be injected separately to the proximity of beads' delivery site. This 
causes uncertainty as to the exact location of the treatment site.  
For TACE therapy, we developed a poly(vinyl alcohol) (PVA) hydrogel-based 
multifunctional delivery system containing iron oxide nanoparticles (IONPs) and silica 
(SiO2) particles that can deliver the drug and the image contrast agent within the same 
package. This allows the drug to be delivered effectively. In addition, the microparticles can 
be monitored via imaging more precisely. The delivery system is also degradable, which 
would allow repeat treatment at the same tumor site. These improvements would lead to 
enhanced treatment and better outcomes for the patients.  
The concept of a multifunctional delivery system demonstrated for TACE therapy can be 
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Chapter 1  
1 Introduction 
1.1 Background and Motivation 
Drug release systems are drug depots that aim to confine the drug's pharmacological 
activity to the target site with a predetermined release profile. The ideal formulation 
should be able to (1) maintain the local concentration within the therapeutic window, (2) 
prolong drug release at the site of disease, (3) protect therapeutics from inactivation or 
degradation, (4) produce little or no systemic toxicity, (5) be tailored to the 
administration route and physiological features of the desired site of action [1]. 
Since the first drug-polymer system was introduced in the mid-1960s [2], controlled 
delivery technologies have undergone profound advancement over the past 60 years. This 
is represented by the move from short-term (1-2 day) delivery formulations in the form of 
tablets or ointments, towards long-term (6-12 months) and modulated formulations in 
micron or nanoscale dosage forms [3]. The choice of drug carriers also evolves from non-
degradable polymers like silicone rubber and ethylene-vinyl acetate to a wide array of 
biodegradable polymers. Of note, hydrogels and nanocarriers composed of biodegradable 
materials dominated the research landscape in the past decade and have established 
promising clinical relevance, and the systems based on nanoparticles are projected to be 
leading the research on targeted delivery in the future [3,4].   
Existing drug delivery systems can be categorized into two types based on the 
administration route and action mechanism. The first group is usually administered via 
oral or intravenous route and reaches the desired site of action through blood circulation. 
Typical delivery platforms are tablets [5] and nanoscale particles such as polymeric 
nanoparticles [6], lipids [7] and micelles [1]. Although controlled release formulations 
offered many advantages over the conventional dosage forms, they are suffering from 
suboptimal pharmacokinetic profiles or poor stability and low bioavailability [8,9]. The 
second group of delivery systems are characterized by wafers, hydrogels, and inhalable or 




site of diseases, leading to locoregional drug delivery. Localized treatment regimens can 
circumvent hepatic first-pass metabolism and gastrointestinal enzymatic degradation and 
bypass different biological barriers, resulting in improved bioavailability [11]. 
The advancements in controlled release techniques expanded drug delivery options and 
fostered safer, more efficient and compliant treatments. In contrast to systemic delivery, 
locoregional drug delivery limits the presentation of the drug to a target site for its release 
and absorption. Drug administration can be achieved through implantation, injection or 
inhalation [10]. This delivery strategy provides a number of advantages over systemic 
administration such as minimally invasive administration, lower total drug dosage and 
fewer adverse side effects. 
Locoregional drug delivery plays a well-defined role in the management of the diseases 
with localized nature. It remains one of the main strategies treating osteoarthritis [12], 
perturbed wounds [13] and a range of ocular disorders [14]. A wide range of treatment 
options is currently in clinical and preclinical investigations, including devices, 
macromolecular drugs (e.g., peptides and proteins) and small molecules [12,14,15]. 
Future research is likely to focus on expanding the drug spectrum, developing long-term 
controlled release formulations and addressing the safety concerns. 
In addition, locoregional delivery of chemotherapeutics extends treatment options in case 
of solid tumors that are easily accessible. Patients undergoing intraductal administration 
of liposomal doxorubicin have shown higher drug concentration in the breast than 
intravenously injected groups, indicating reduced systemic toxicity [16]. In the case of 
ovarian cancer, Lu et al. found that intraperitoneal treatment provided sustained drug 
levels in the peritoneal cavity with lower systemic drug exposure [17]. Similarly, in the 
postsurgical management of glioblastoma, implantable Gliadel® wafer could provide a 
drug concentration up to 1200 times higher than the systemic route with no significant 
safety concerns [18,19]. Locoregional treatments have also demonstrated promising 
results as the alternative or adjuvant to other forms of treatment in managing lung and 




Decades of experience in locoregional drug delivery have delivered meaningful benefits 
to an appreciable number of patients and imparted additional requirements for controlled 
release systems. First, the retention time of drug depots in the targeted site can be 
extended. Delivery systems with mucoadhesive and drug-protecting attributes would be 
highly desirable in such circumstances [22]. Second, drug permeation and absorption 
should be improved. In this context, drug carriers that are charged, lipophilic and small in 
dimension will be of great value [23,24]. In image-guided locoregional delivery like 
transarterial embolization (TACE), controlled release systems with CT/MRI detectability 
would be highly beneficial [25]. In addition, for the best treatment outcome, co-delivery 
systems might be necessary [25,26]. Last but not least, in consideration of 
biocompatibility and repeated drug administration, the delivery system should be able to 
degrade without forming toxic substances in vivo.  
The realization of the desired drug delivery systems relies upon novel material strategies. 
The significant progress in nanotechnology and polymer science offers a great 
opportunity. It can combine the intrinsic strengths of macroscale systems (e.g., 
hydrogels) with properties (e.g., antimicrobial and imageable) of nanoparticles. This 
combinational system allows a multifunctional delivery formulation. A wide range of 
nanoparticles such as superparamagnetic iron oxide nanoparticles (SPIONs) [26–28], 
silica nanoparticles (SiNPs) [29–31], lipid nanoparticles (LNPs) [32] were successfully 
incorporated into hydrogels through physical or chemical interactions. The incorporation 
of nanocarriers provides a tool to alter the mechanical strength, drug release and hydrogel 
degradation. These manipulations can be done by varying the concentration of nano 
components in the gel matrix [30,31,33,34]. Compared with the delivery systems based 
on a single platform, combinational systems offer expanded spectrum of loadable drugs 
and prolonged drug release [35]. In addition, the nanoparticle-hydrogel interaction adds a 
degree of freedom in regulating drug release and polymer degradation [27]. 
To conclude, locoregional drug delivery has gained increasing importance for treating 
disease with localized nature. Drug delivery systems composed of hydrogels and 
nanoparticles demonstrate huge potential in fulfilling the stringent requirements placed 




grow, it is expected that novel drug release systems will be in high demand. We believe 
the development and optimization of multifunctional drug delivery systems will deepen 
the understanding of fundamental science and, more importantly, lead to significant 
clinical impact in the coming decades. 
1.2 Objectives 
In previous work in our laboratory, we explored PVA-iron oxide nanoparticles (IONPs) 
nanocomposite hydrogels. We have shown that the incorporation of IONPs contributes to 
the crosslinking of the PVA and leads to a ‘degradable’ hydrogel system [27]. 
The overall objective of this thesis is to explore various formulations to improve and 
expand their applications in locoregional drug delivery. To achieve the objectives, a 
series of specific goals are set up and listed below. 
1. To develop a range of delivery systems in the form of nanoparticles or composite 
hydrogels. 
2. To characterize the delivery systems in terms of size, morphology, composition, 
and magnetic properties. 
3. To investigate drug release profiles at different environmental conditions. 
4. To study the degradation/dissolution of the drug carriers. 
As shown in Figure 1.1, the first stage (Chapter 3) of this thesis is regarded as a 
continuation of our prior work. Magnetic PVA-IONP hydrogels were prepared and 
shaped into microparticles using microfluidics for doxorubicin delivery with IONPs co-
localized for visualization of drug location at the tumor site. Degradability of the carrier 
also allows for repeat TACE treatment. In the second stage (Chapter 4), non-porous silica 
nanoparticles (SiNPs) were explored as a carrier for bioactive protein and peptide N-94 
for the treatment of dry eye disease. Finally, a modified microbeads formulation 
composed of silica microparticles, IONP and PVA hydrogel (PVA-SiO2-IONP) was 
developed and characterized for doxorubicin delivery. The optimized system 
demonstrated an increased drug loading and tunable release profile compared to the 





Figure 1.1 Schematic of the interrelationship of the research work described in 
Chapter 3-5. 
1.3 Thesis Structure 
This thesis is structured into 6 chapters. Chapter 3-5 will describe three projects towards 
the development and improvements of locoregional drug delivery systems. 
• Chapter 1 Introduction 
This chapter provides a general introduction of locoregional drug delivery and controlled 
release delivery systems, as well as the objectives and outline of this thesis. 
• Chapter 2 Literature Review 
This chapter gives an in-depth review of the rationales of designing a microparticulate 
drug delivery system. Topics including transarterial chemoembolization, dry eye 
didsease, design criteria for drug-eluting microparticles, design rationale for 




• Chapter 3 Development of Multifunctional PVA-IONP Microparticles for TACE 
This chapter introduces the design of PVA-IONP microparticles as potential drug-eluting 
beads (DEBs) in TACE treatment.  Microparticles were fabricated via microfluidic 
technique. The MRI images of microbeads of various concentrations were taken to 
examine the contrast enhancement. Doxorubicin loading and release were performed. 
Degradation studies were performed in the acidic and physiological pH conditions.  
• Chapter 4 Development of a Multifunctional Bioactive Protein/Peptide Delivery 
System for Dry Eye Disease 
This chapter describes the work on SiNPs as protein carriers in the application of dry eye 
treatment. Adsorption kinetics and isotherm were studied and modelled using lysozyme 
as the model protein. The release profile of lysozyme and a bioactive peptide, N-94, were 
studied and compared. Dissolution of SiNPs was investigated in a period of one month. 
Cell studies were performed to examine the functional equipotency of N-94 to its parent 
protein, lacritin, and the biocompatibility of the delivery system. 
• Chapter 5 Development of Multifunctional PVA-SiO2-IONP Microparticles for 
TACE 
This chapter presents the modification and improvements of PVA-IONP microbeads. 
Silica microparticles were introduced into the composite hydrogel. The dependency of 
particle diameter on flow rates of the continuous phase and dispersed was explored. The 
effect of drug loading, pH and ionic concentration on the drug elution profile were 
investigated. The dissolution of PVA-SiO2-IONP microparticles was qualitatively 
characterized.  
• Chapter 6 Conclusions and Recommendations 
This chapter provides the summary, significance and future directions of the research 





[1] F. Pittella, H. Cabral, Y. Maeda, P. Mi, S. Watanabe, H. Takemoto, H.J. Kim, N. 
Nishiyama, K. Miyata, K. Kataoka, Systemic siRNA delivery to a spontaneous 
pancreatic tumor model in transgenic mice by PEGylated calcium phosphate hybrid 
micelles, Journal of Controlled Release. 178 (2014) 18–24.  
[2] R.S. Langer, N.A. Peppas, Present and future applications of biomaterials in 
controlled drug delivery systems, Biomaterials. 2 (1981) 201–214.  
[3] K. Park, Controlled drug delivery systems: past forward and future back, J Control 
Release. 190 (2014) 3–8.  
[4] Y.F. Tan, L.L. Lao, G.M. Xiong, S. Venkatraman, Controlled-release 
nanotherapeutics: State of translation, Journal of Controlled Release. 284 (2018) 
39–48.  
[5] S. Kumar, A.K. Singh, S.K. Prajapati, V.K. Singh, Formulation and Evaluation of 
once daily sustained release matrix tablets of Aceclofenac using natural gums, 
Journal of Drug Delivery and Therapeutics. 2 (2012).  
[6] S. Acharya, S.K. Sahoo, PLGA nanoparticles containing various anticancer agents 
and tumour delivery by EPR effect, Adv. Drug Deliv. Rev. 63 (2011) 170–183.  
[7] T.X. Nguyen, L. Huang, M. Gauthier, G. Yang, Q. Wang, Recent advances in 
liposome surface modification for oral drug delivery, Nanomedicine. 11 (2016) 
1169–1185.  
[8] S. Senapati, A.K. Mahanta, S. Kumar, P. Maiti, Controlled drug delivery vehicles 
for cancer treatment and their performance, Signal Transduct Target Ther. 3 (2018).  
[9] N.R. Mathias, M.A. Hussain, Non-invasive Systemic Drug Delivery: Developability 
Considerations for Alternate Routes of Administration, Journal of Pharmaceutical 
Sciences. 99 (2010) 1–20.  
[10] F. Ramazani, C.F. van Nostrum, G. Storm, F. Kiessling, T. Lammers, W.E. 
Hennink, R.J. Kok, Locoregional cancer therapy using polymer-based drug depots, 
Drug Discov. Today. 21 (2016) 640–647.  
[11] G. Pulivendala, S. Bale, C. Godugu, Inthalation of sustained release microparticles 
for the targeted treatment of respiratory diseases, Drug Deliv Transl Res. 10 (2020) 
339–353.  
[12] P. Maudens, O. Jordan, E. Allémann, Recent advances in intra-articular drug 





[13] R. Dimatteo, N.J. Darling, T. Segura, In situ forming injectable hydrogels for drug 
delivery and wound repair, Adv. Drug Deliv. Rev. 127 (2018) 167–184.  
[14] A. Patel, K. Cholkar, V. Agrahari, A.K. Mitra, Ocular drug delivery systems: An 
overview, World J Pharmacol. 2 (2013) 47–64.  
[15] J.W. Park, S.R. Hwang, I.-S. Yoon, Advanced Growth Factor Delivery Systems in 
Wound Management and Skin Regeneration, Molecules. 22 (2017).  
[16] V. Stearns, T. Mori, L.K. Jacobs, N.F. Khouri, E. Gabrielson, T. Yoshida, S.L. 
Kominsky, D.L. Huso, S. Jeter, P. Powers, K. Tarpinian, R.J. Brown, J.R. Lange, 
M.A. Rudek, Z. Zhang, T.N. Tsangaris, S. Sukumar, Preclinical and Clinical 
Evaluation of Intraductally Administered Agents in Early Breast Cancer, Science 
Translational Medicine. 3 (2011) 106ra108.  
[17] Z. Lu, M. Tsai, D. Lu, J. Wang, M.G. Wientjes, J.L.-S. Au, Tumor-penetrating 
microparticles for intraperitoneal therapy of ovarian cancer, J. Pharmacol. Exp. 
Ther. 327 (2008) 673–682.  
[18] T.A. Juratli, G. Schackert, D. Krex, Current status of local therapy in malignant 
gliomas — A clinical review of three selected approaches, Pharmacology & 
Therapeutics. 139 (2013) 341–358.  
[19] T. AOKI, R. NISHIKAWA, K. SUGIYAMA, N. NONOGUCHI, N. KAWABATA, 
K. MISHIMA, J. ADACHI, K. KURISU, F. YAMASAKI, T. TOMINAGA, T. 
KUMABE, K. UEKI, F. HIGUCHI, T. YAMAMOTO, E. ISHIKAWA, H. 
TAKESHIMA, S. YAMASHITA, K. ARITA, H. HIRANO, S. YAMADA, M. 
MATSUTANI, A Multicenter Phase I/II Study of the BCNU Implant (Gliadel ® 
Wafer) for Japanese Patients with Malignant Gliomas, Neurol Med Chir (Tokyo). 
54 (2014) 290–301.  
[20] R. Rosière, T. Berghmans, P. De Vuyst, K. Amighi, N. Wauthoz, The Position of 
Inhaled Chemotherapy in the Care of Patients with Lung Tumors: Clinical 
Feasibility and Indications According to Recent Pharmaceutical Progresses, Cancers 
(Basel). 11 (2019).  
[21] L. Shen, M. Xi, L. Zhao, X. Zhang, X. Wang, Z. Huang, Q. Chen, T. Zhang, J. 
Shen, M. Liu, J. Huang, Combination Therapy after TACE for Hepatocellular 
Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy 
versus Sorafenib, Cancers (Basel). 10 (2018).  
[22] S. Duggan, W. Cummins, O. O’ Donovan, H. Hughes, E. Owens, Thiolated 
polymers as mucoadhesive drug delivery systems, European Journal of 
Pharmaceutical Sciences. 100 (2017) 64–78.  
[23] A. Vashist, A. Kaushik, A. Vashist, R.D. Jayant, A. Tomitaka, S. Ahmad, Y.K. 
Gupta, M. Nair, Recent trends on hydrogel based drug delivery systems for 




[24] S. Zhang, H. Gao, G. Bao, Physical Principles of Nanoparticle Cellular Endocytosis, 
ACS Nano. 9 (2015) 8655–8671.  
[25] A.L. Lewis, S.L. Willis, M.R. Dreher, Y. Tang, K. Ashrafi, B.J. Wood, E.B. Levy, 
K.V. Sharma, A.H. Negussie, A.S. Mikhail, Bench-to-clinic development of 
imageable drug-eluting embolization beads: finding the balance, Future Oncology. 
14 (2018) 2741–2760.  
[26] M.P. Kesavan, S. Ayyanaar, V. Vijayakumar, J. Dhaveethu Raja, J. Annaraj, K. 
Sakthipandi, J. Rajesh, Magnetic iron oxide nanoparticles (MIONs) cross-linked 
natural polymer-based hybrid gel beads: Controlled nano anti-TB drug delivery 
application, J Biomed Mater Res A. 106 (2018) 1039–1050.  
[27] A.D. Bannerman, X. Li, W. Wan, A ‘degradable’ poly(vinyl alcohol) iron oxide 
nanoparticle hydrogel, Acta Biomaterialia. 58 (2017) 376–385.  
[28] D.-H. Kim, T. Choy, S. Huang, R.M. Green, R.A. Omary, A.C. Larson, 
Microfluidic Fabrication of MEAN-Eluting Magnetic Microspheres, Acta Biomater. 
10 (2014) 742–750.  
[29] R. Guo, X. Du, R. Zhang, L. Deng, A. Dong, J. Zhang, Bioadhesive film formed 
from a novel organic–inorganic hybrid gel for transdermal drug delivery system, 
European Journal of Pharmaceutics and Biopharmaceutics. 79 (2011) 574–583.  
[30] P. Zhao, H. Liu, H. Deng, L. Xiao, C. Qin, Y. Du, X. Shi, A study of chitosan 
hydrogel with embedded mesoporous silica nanoparticles loaded by ibuprofen as a 
dual stimuli-responsive drug release system for surface coating of titanium implants, 
Colloids and Surfaces B: Biointerfaces. 123 (2014) 657–663.  
[31] H.H.C. de Lima, V.L. Kupfer, M.P. Moisés, M.R. Guilherme, J. de C Rinaldi, S.L. 
Felisbino, A.F. Rubira, A.W. Rinaldi, Bionanocomposites based on mesoporous 
silica and alginate for enhanced drug delivery, Carbohydr Polym. 196 (2018) 126–
134.  
[32] C. Desfrançois, R. Auzély, I. Texier, Lipid Nanoparticles and Their Hydrogel 
Composites for Drug Delivery: A Review, Pharmaceuticals (Basel). 11 (2018).  
[33] A.K. Gaharwar, C.P. Rivera, C.-J. Wu, G. Schmidt, Transparent, elastomeric and 
tough hydrogels from poly(ethylene glycol) and silicate nanoparticles, Acta 
Biomaterialia. 7 (2011) 4139–4148.  
[34] A. Nasajpour, S. Ansari, C. Rinoldi, A.S. Rad, T. Aghaloo, S.R. Shin, Y.K. Mishra, 
R. Adelung, W. Swieszkowski, N. Annabi, A. Khademhosseini, A. Moshaverinia, 
A. Tamayol, A Multifunctional Polymeric Periodontal Membrane with Osteogenic 
and Antibacterial Characteristics, Advanced Functional Materials. 28 (2018).  
[35] T.R. Hoare, D.S. Kohane, Hydrogels in drug delivery: Progress and challenges, 




Chapter 2  
2 Literature Review 
2.1 Hepatocellular Carcinoma and Transarterial 
Chemoembolization 
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver 
and the third most common cause of cancer-related mortality in the world [1,2]. The 
treatment allocation for HCC is dependent on the stage of disease, liver function, and 
performance status. Table 2.1 provides an overview of the most commonly used HCC 
management guideline- Barcelona Clinic Liver Cancer (BCLC) staging system. With 
improved surveillance strategy of patients with cirrhosis and chronic liver disease and 
advanced diagnostic methods, more patients are detected at early-stage HCC [3]. 
Curative treatments, including hepatic resection, liver transplantation, and radiofrequency 
ablation (RFA) are recommended for patients diagnosed with early-stage HCC [4]. For 
HCC that is not amenable to curative procedures, palliative therapies via TACE or 
systematic chemotherapy are offered [5]. 
Table 2.1 Barcelona Clinic Liver Cancer (BCLC) staging system with treatment 
recommendations. Adapted from reference [6]. 
 
Transarterial chemoembolization plays multiple roles in the clinical management of 




first-line treatment for patients with intermediate stage HCC (BCLC stage B) [6]. TACE 
is used in cases with recurrent HCC after curative treatments [7,8]. TACE has also been 
used as a bridge for patients waiting to fulfill criteria for transplantation when donor 
becomes available [9,10]. Moreover, TACE represents a valuable component in 
multimodal treatments for downsizing large tumors [11].  
Table 2.2 Roles of TACE in the management of HCC. 
 
The principle of TACE revolves around the dual blood supply of the liver. The normal 
tissue of the liver receives most (75%-85%) of its blood supply from the portal vein and 
receives the remaining from the hepatic artery. On the other hand, liver tumors receive 
~90% of their blood supply from the hepatic artery [5]. It has been reported that the 
embolization via hepatic arteries would have minimal ischemic damage on normal 
hepatic parenchyma, as its dominant blood supply from a portal vein is unaffected [12]. 
In addition, unlike oral or intravenous delivery, the chemotherapeutic effect of the drugs 
is reserved as this approach bypasses the first-pass metabolism [13].  
The success of the TACE procedure heavily relies on imaging techniques and requires a 
multidisciplinary tumor board consist of a surgeon, clinical oncologist and interventional 
radiologist [14]. In a typical TACE therapy, pre-treatment imaging consisting of a 
multiphasic computed tomography (CT) or dynamic contrast-enhanced magnetic 
resonance imaging (MRI) of the liver must be obtained preferably within four weeks of 
the planned TACE intervention [15]. The pre-treatment imaging aims to acquire anatomic 
information to aid in planning the procedure [15,16]. Figure 2.1 schematically describes 
the TACE procedure. During a TACE, patients will be given a local anesthetic. The 
interventional radiologist places a catheter into the patient's femoral artery and moves the 
catheter up until it reaches the hepatic artery in the liver. Three-dimensional vascular 
Palliative treatment for intermediate stage HCC (BCLC stage B)
Treatment/prevention tool for recurrent HCC after curative treatments by surgery or ablation
Bridging or downstaging tool to liver transplantation
Neoadjuvant therapy to downsize tumor prior to liver resection




images (angiogram) are necessary to identify the appropriate tumor-feeding branches. An 
X-ray is taken by infusing radio-opaque contrast agents through the catheter. Drugs/drug 
carriers and embolic materials are delivered separately or simultaneously depending on 
the techniques and delivery systems. The injection is stopped when the stasis flow of 
contrast agents existed. Angiography is repeated, and embolization is continued until all 
blushed tumors disappeared [17]. In post-procedure care, CT scans are performed to 
determine tumor response recurrence 4-8 weeks after the procedure. Sequential TACE 
procedures can be performed in 4-16 weeks if any recurrent tumor is identified [12].  
 
Figure 2.1 Schematic demonstration of TACE. Figure reprinted with permission 
from [18]. 
TACE can be classified as conventional TACE (cTACE) and drug eluting beads (DEB)-
TACE. The cTACE involves an arterial infusion of an emulsion containing 
chemotherapeutics in iodinated oil (Lipiodol®) followed by injection of embolic agents to 
occlude the same tumor vasculature. A major advantage of cTACE is its radiopaque 
iodinated oil allows intra-procedure visualization of the drugs, which is helpful to 
optimize the imaging guidance. The drawbacks of cTACE include the rapid release of 
drug from Lipiodol associated with the weak bonding between the doxorubicin and the 
carriers [19]. Other drawbacks underline the unstable and unpredictable post-treatment 
outcomes, which might be due to the variants in the procedure, as cTACE is not a well-
standardized procedure and can be largely dependent on the medical specialists' 
experience,  treatment devices available and the therapeutic agents injected [20]. 
The limitations of cTACE led to its gradual replacement by DEB-TACE. DEB-TACE 




of chemotherapeutic agents together with vessel occlusion. The DEBs essentially serve as 
a drug carrier, contrast agent and embolic agent. The integration of multiple functions is 
achieved by the appropriate design of the size and composition of the matrix. DEBs are 
typically in the diameter of 40-900 𝜇m, making them large enough for vascular 
embolization [21]. Drug loading is performed prior to the TACE procedure by immersion 
methods and typically takes 20 min to 2 h to complete depending on the bead size and 
materials [22,23]. The loading is driven by ionic interactions between the drug molecules 
with polymeric backbone. The contrast medium could be incorporated by physical 
mixing with DEBs [24,25] or via covalent coupling with the polymeric backbone [26]. 
Imageable DEBs can also be prepared by entrapment of iron oxide nanoparticles (IONPs) 
[27–29]. Of note, DEB-TACE is performed in a more standardized way as compared to 
cTACE, both during preparation and administration. The standardization leads to more 
homogenous and stable patient data [30]. In some clinical studies, DEB-TACE has shown 
improved tolerability, better tumor response and lower systemic toxicity than cTACE 
[31,32].  
2.2 Dry Eye Disease and Treatments 
Dry eye disease (DED) is a multifactorial disease of the tear and ocular surface, 
characterized by hyperosmolarity, tear film instability, ocular surface inflammation, and 
visual discomfort [33]. These changes in tear composition activate stress signaling 
pathways in the ocular surface epithelium and resident immune cells, which triggers the 
production of inflammatory mediators to recruit and activate immune cells and produce 
cytokines, such as interleukin (IL)-1𝛽, IL-6, and tumor necrosis factor (TNF)-𝛼 [34]. The 
secretion of cytokines would initiate a vicious cycle and further damage the cornea and 
lacrimal glands, decline the tear function and worse the symptoms [34,35]. 
The current DED treatments focus on minimizing the inflammation and supplementing 
the tear film components [36]. The topical application of lubricating agents, anti-
inflammatory therapeutics, biological tear components through eye drops remains the 




plug insertion is encouraged to prolong the resident time of aqueous and artificial tears on 
the ocular surface [38]. 
The topical administration is often associated with two challenges: the low ocular 
bioavailability of the drug and the unfavorable long-term use of the commonly prescribed 
therapeutics [36,37]. Less than 5% of topically applied drug doses can reach deeper 
ocular tissues due to the complex anatomical and physiological barriers of eyes [39]. 
Reflex tearing, blinking, nasolachrymal drainage and metabolic degradation impede 
sufficient time residence and deep drug permeation [40]. As a result, frequent dosing of 
the drugs at high concentrations is required to deliver sufficient therapeutic effects. The 
poor patient adherence and high drug dosage could result in extreme fluctuations in drug 
ocular concentrations and systemic drug distribution, leading to undesirable side effects 
[37].  
To prolong the ocular residence time of the therapeutics and minimize the oscillations in 
the drug concentrations, numerous drug delivery systems have been developed. 
Nanomicelles, nanoparticles, liposomes, and hydrogels were loaded with drugs and can 
provide an effective drug concentration in the eye for a week [41]. In addition to being 
used solely, such systems could be included in other devices such as contact lens. The 
liposome-laden lens have demonstrated a controlled drug release over a period of 8 days 
[40].  
The potential risks associated with the long-term use of commonly prescribed drugs 
posed a challenge for DED treatment via topical route. Steroids are one of the most 
effective and rapid medications for DED. However, prolonged use is not recommended 
due to the risks of developing an ocular infection, glaucoma, and cataract [42]. Topical 
instillation of cyclosporine can lead to complications such as lid maceration and corneal 
epitheliopathy [43]. Another alternative treatment is lifitegrast, the only U.S. Food and 
Drug Administration (FDA)-approved drug for both signs and symptoms of DED [44]. 
The adverse events consist of ocular irritation and hyperthermia. Systemic effects are 
headaches, erythema, and musculoskeletal pain. Clinical studies on long-term safety 




The adverse ocular events associated with commonly prescribed molecules have 
encouraged research and development of biotherapeutics as alternatives. Among them, 
bioactive tear proteins have emerged as promising candidates. 
Lacritin is a growth-factor-like tear protein (~ 25 kDa) that is selectively downregulated 
in dry eye [45,46]. It is produced by human lacrimal acinar cells, corneal, conjunctival, 
and salivary epithelia [47]. Lacritin has demonstrated mitogenic and cytoprotective 
properties on human corneal epithelial cells (HCECs) and can promote basal tearing that 
is sustained for at least 4 hours when topically instilled in rabbits [46–48]. It was found 
that lacritin’s C-terminal is mitogenic and has a amphipathic 𝛼-helical structure [49]. In 
addition, its C terminus targets cell surface syndecan-1 (SDC1), a transmembrane protein 
that regulates mitogenic signaling, making lacritin a potential cell-targeting strategy for 
DED. 
Various C-terminal fragments of lacritin have been produced via chemical synthesis. For 
example, N-65 represents a lacritin truncation mutant lacking 65 N-terminal amino acids 
[50]. Other lacritin peptides such as N-55, N-74, N-94, and N-104 were synthesized, as 
described elsewhere [51]. The synthetic surrogates have demonstrated antimicrobial 
properties and they are effective in stabilizing the tear lipid layer and maintaining 
epithelial homeostasis [52].  
The combinational use of protein-based therapeutic agents with drug delivery systems 
offers a promising tool to treat DED. The topical administration of lacritin molecules or 
its fragments may contribute to a restored team film microenvironment, particularly 
under dry eye conditions where they are deficient [47]. As biomolecules are prone to 
decomposition on the inflammatory and oxidative ocular surface, the use of drug delivery 
systems, in return, can potentially protect and allow sustained availability of protein 
therapeutics [53].  
For dry eye treatment, future efforts should be dedicated to discovering safer drug 
molecules and more effective delivery options. The replacement of steroid therapy with 
natural tear components can provide a long-term solution by physiologically rescuing the 




advancement in carrier systems is expected to facilitate the delivery of drugs, concentrate 
drugs at the target site, and prolong their corneal residence time, ultimately reducing dose 
and dosing frequency. 
2.3 Chemotherapeutic Agents 
For TACE, the most common sole-agent anticancer drugs used are the anthracycline 
group. In published cohort and randomized studies, anthracycline antibiotic doxorubicin 
(DOX) takes up 36% of the cases while epirubicin represents 12% of the records. Other 
popular chemotherapy agents include cisplatin (31% of the cases), mitoxantrone (8%), 
mitomycin (8%), and poly(stylene-co-maleic acid)-conjugated neocarzinostatin 
(SMANCS, 5%) [54]. The chemical formula and structure of commonly used anticancer 
drugs are shown in Table 2.3. Notably, the criteria to decide the dosing regimen is not 
standardized: some physicians prefer to determine it based on patient’s body surface area, 
weight, tumor burden or bilirubin level, while others prefer to use a fixed dose [55]. The 
usual dose for DOX is 40-100 mg while cisplatin between 50-100 mg [14,15]. Some 
randomized clinical studies showed no significant differences in survival rate between the 
single-drug treatment of DOX and cisplatin or epirubicin [56–59]. Moreover, to date, 
there is no evidence of the superiority of any single cytotoxic anticancer drug over other 











Table 2.3 Summary of commonly used cytotoxic anticancer drugs for TACE. 
 
While the dosing regimen is not standardized, the EASL-EORTC [(European Association 
for the Study of the Liver) or (Response Evaluation Criteria in Solid Tumors)] clinical 
practice guidelines provide a general rule for the dose of DOX. The recommended DOX 
dose per treatment is 50-75 mg to a maximum value of 150 mg (75 mg/m2 body surface 
area) [60]. Patients may receive 3- 4 TACE treatments within six months, with each 
session being ~3 to 4 weeks apart. The maximum recommended lifetime dose of DOX is 
900 mg (450 mg/m2), in correlation to the cardiac toxicity when the drug is administered 
systemically [61]. 
2.4 Drug-eluting Microparticles and Commercial 
Products 
Over the previous decades, several DEBs have become commercially available (Table 
2.4). The most commonly used microparticles in clinical practice are DC BeadTM/LC 
BeadTM (Biocompatibles, United Kingdom), the radio-opaque version of DC Bead: DC 




(BioSphere Medical, France), OncozeneTM/Embozene TANDEMTM (Varian Medical 
Systems, United States), and LifePearl® (Terumo International Systems, Belgium). 
Commercial DEBs are typically offered in a size range (e.g., 70-150 μm, 100-300 μm, 
300-500 μm, 500-700 μm). The most common bead sizes are 100-300 μm, 300-500 μm 
and 500-700 μm [62], while DEBs in 100-300 μm provide the a better treatment response 
and fewer major complications than beads with larger diameters [63,64]. 
Table 2.4 Overview of commercially available DEBs. 
 
Y: yes, N: no. 
Commercial DEBs carry negative charges and allow the loading of chemodrugs with 
counter ions (e.g., DOX, epirubicin and cisplatin). DC BeadTM is made of PVA 
functionalized with sulfonate groups on the bead surface [65]. DC BeadTM microparticles 
are usually packaged in 2 mL vials at a hydrated state in a sodium phosphate solution and 
provide a DOX loading capacity of up to 45 mg/mL [64,65]. DC Bead LUMITM is 
derived from DC BeadTM and the PVA backbone is covalently bonded with imaging 
moieties iodine, therefore allows standard fluoroscopy and CT imaging [66]. 
HepaSphereTM is a poly(vinyl alcohol-co-acrylic acid) microsphere packaged in a dry 
state. This type of beads expands to four times in volume upon exposure to saline. The 




beads and can achieve a DOX loading ~40 mg/mL beads [22]. Likewise, TANDEMTM is 
composed of poly(methylacrylic acid) microspheres with perfluorinated coating. The 
pendant carboxylate groups allow up to 50 mg/ml loading of DOX [67,68]. LifePearl® 
beads consist of a poly(ethylene glycol) (PEG) modified with sulfonate groups and can 
provide a DOX loading at ~37.5 mg/ml [69]. 
The in vitro drug loading and eluting profile provide helpful information to determine the 
dosing regimen and predict the pharmacokinetics of the drugs. Baere et al. conducted a 
comparative study of the four DEBs (DC BeadTM, HepaSphereTM, Embozene TANDEM 
TM and LifePearl®) [22]. All four types of DEBs can reach maximum loading in ~ 2 h, 
with larger particles generally take a longer time to reach the plateau. The drug elution 
profile was examined under sink condition in flow cells, all four types of DEBs exhibited 
incomplete drug release, and the maximum release achieved within 5 hours. The results 
also showed a decline in eluted DOX, indicating degradation and adsorption of DOX at 
neutral pH [70].  
The future direction in DEBs is in the development of size-tunable, imageable, 
degradable beads. DEBs that are in support of combination treatments is another research 
focus. The design criteria and rationales for DEBs will be discussed in detail in the 
following section. 
2.5 Design Criteria for Drug-eluting Microparticles 
Multiple parameters that could significantly affect the clinical benefits of DEB-TACE. 
The morphological characteristics can affect the vascular distribution and occlusive 
behavior of the microparticles. Imageability/detectability is useful in guiding the 
intervention. More importantly, the co-localization of contrast agent with drug allows a 
more precise tracking of drug distribution relative to the position of the tumor. 
Targetability allows tumor-specific delivery through magnetic resonance navigation 
(MRN), potentially minimizing the unwanted toxicity to healthy tissue. Advantages of 
controlled release formulations include an effective drug concentration in tumor tissue 
and reduction of systemic exposure. The purpose of having degradable DEBs is to 




multiple therapeutics is desired as it could enable comprehensive and multimodal 
therapies for certain cancer patients. A multifunctional delivery system, as its name 
suggests, can exert multiple functions with one platform. Such system is highly 
advantageous for the locoregional treatment of complex diseases, such as cancer. In this 
section, the design considerations for multifunctional drug-eluting microparticles are 
rationally discussed. 
2.5.1 Shape 
The shape of DEBs has a significant impact on the efficacy and safety of the TACE 
treatment. Non-spherical poly(vinyl alcohol) (PVA) particles emerged in the 1970s as a 
permanent embolic option complementing degradable gelatin sponge. It was marketed as 
Ivalon® and distributed as a sheet or block form. For each use, PVA particles were 
manually produced by a sawblade or a rotating rasp. And the shavings were subsequently 
filtered with sieves and sorted into particles of different sizes [71]. The resulting PVA 
particles are irregular in shape due to the preparation method. This led to two issues: (1) 
the actual size does not coincide with the dimension provided by the vendor and (2) the 
tendency for aggregation. Derdeyn et al. [72] studied the size of PVA particles and found 
that many were larger than the advertised minimum size. This could mislead the 
radiologist in selecting the agent compatible with the dimension of vessels to be 
occluded. In addition, the PVA particles possessed a huge size deviation. The oblong 
particles may have an extremely short axis (< 20 μm) or sharp fragments. Such fractions 
could cause off-target embolization or end-organ damage [73]. The irregular surface and 
broad size distribution also led to clumps that made catheter administration very difficult. 
In addition, this tendency to form aggregates resulted in a larger effective size, which 
contributed to a more proximal rather than distal occlusion [74]. Nevertheless, particulate 
non-spherical PVA holds its utility in widespread scenarios where proximal occlusion is 
desired, such as in embolizing uterine fibroid, managing epistaxis, treating solid organ 
bleeding [75,76]. In situations where deeper tissue penetration is required, spherical 
particles would be the more suitable option.  
The clinical disadvantages of irregular-shaped PVA particles prompted the development 




products have become available. Depending on the purpose of the application, 
commercial products can be classified into two categories: bland embolic agents (e.g., 
Contour SETM, Embosphere® and Bead Block®) and embolic DEBs (e.g., DC/LC 
BeadTM, HepaSphere/QuadraSphereTM, Embozene TANDEMTM and LifePearl®). 
Microspheres with calibrated sizes have demonstrated improved distal penetration and 
physiologic outcomes than non-spherical PVA particles, hence becoming a preferred 
choice for physicians [77–79].   
2.5.2 Size and Size Distribution 
Size and size distribution are critical in determining flow behavior and physiologic 
outcome of the DEB-TACE treatments. Smaller particles tend to penetrate deeper into the 
vasculature and reach more distal locations [78,80]. Regarding the size distribution, most 
commercial products are offered in a size range (e.g., 70-150 μm, 100-300 μm, and 300-
500 μm) rather than in one size. A broad size range did not render significant targeting 
disadvantages over a narrow one. In a comparative study conducted by Laurent et al., 
microspheres with a broader size distribution demonstrated similar vasculature 
distribution in animal models as compared to narrow microparticles [81]. This study 
suggests that microparticles with a broad size range might provide the same level of 
vessel embolization as unisize beads.  
Moreover, the size and shape of DEBs play a critical role in regulating the drug-eluting 
profile. Smaller DEBs provide faster release than larger ones due to the greater surface-
to-volume ratio [82]. In addition, irregular-shaped DEBs produced a faster drug release 
rate compared to microspheres. This might be associated with a larger surface area 
[83,84]. As such, the geometrical factors of DEBs must be considered in the development 
of DEBs to achieve the desired embolization and drug delivery outcome.  
2.5.3 Imageability/Detectability 
As stated in section 2.1, vascular imaging plays an integral role in TACE by providing 
intra-procedural guidance for catheters, confirming complete occlusion, and post-
procedural monitoring on beads distribution and tumor progression [85,86]. DEBs with 




possibly be used as an indicator of drug/bead distribution and fulfil the imaging needs 
without multiple usages of toxic contrast agents. Imageable drug delivery systems were 
initially prepared by mixing radiopaque Lipiodol emulsions with the drug. However, 
animal studies revealed the discordance between the contrast and drug. More specifically, 
the spatial distribution of contrast agents did not correlate with the distribution of the 
drug. This could be due to the instability of the formulation and rapid passage of the drug 
to the systemic circulation after administration, as the bonding between the Lipiodol 
emulsion and the drug is relatively weak [5,30,87]. 
DEBs with integrated contrast agents are therefore highly sought-after in clinical practice. 
Since the chemotherapeutics and contrast components are held together, the location of 
DEBs represents the exact drug location. In addition, the intensity of the signal can be an 
indicator of local drug concentration. The most common approach to constructing an 
imageable DEB system is by incorporating magnetic nanoparticles (NPs) into the 
hydrogel matrix. The generation of large magnetic dipoles thereby local magnetic field 
gradient within the NPs will strongly alter the relaxation times of surrounding water 
protons, resulting an enhanced imaging contrast [88]. Commonly used magnetic NPs are 
superparamagnetic iron oxide nanoparticles (SPIONs), tantalum NPs, cobalt NPs, and 
lanthanide moieties [89].  
2.5.4 Targetability 
Targeted drug delivery represents another future direction for locoregional therapy, and 
this can be achieved by magnetic targeting. In this approach, magnetic particles are 
embedded in the drug carriers to localize the drugs at the site of action. The drug-carrier 
complex is first injected intra-arterially. High-gradient, external magnetic fields 
generated by rare earth permanent magnets are used to maneuver magnetic particles to 
achieve an exclusive drug accumulation at the tumor site [90]. The magnetic carriers 
contain SPIONs have demonstrated improved tumor suppressive behaviors in treating 
brain [91,92], lung [93] and bone cancers [94]. The limitations with magnetic targeting 
are that the gradient-induced forces decline rapidly with the distance from the magnet, 




drawbacks limit the application of magnetic targeting to superficial tumors or small 
animals. 
Magnetic resonance navigation (MRN), also referred to as magnetic resonance targeting 
(MRT), has been developed to overcome the weakness of magnetic targeting. Clinical 
MRI coils are explored as the source of steering (propelling) force. The distance from the 
magnet is no longer a restraint as MRI gradient coils can offer constant amplitude over 
depth as distant as 50 cm [95]. The physical principle behind MRT is to use the three 
orthogonal gradient coils inside the MRI bore to induce a 3D directional magnetic force 
to propel the magnetic particles along a predefined trajectory [96]. The majority of the 
state-of-art facilities use MRI machines with a magnetic field strength of 1.5 or 3T [97]. 
The clinical magnets (≥1.5 T) are considered to be sufficient for saturating the 
ferromagnetic materials throughout the body so a maximum magnetic force/response 
could be exerted on the particles [96,98].  
A significant challenge with MRN is that the magnetic gradient amplitudes are 
insufficient for navigating smaller particles. For navigation purposes, MRI gradient coils 
need to generate a propelling force that could overcome the drag force. The magnetic 
force increases at a cubic power with the particle radius (proportional to the volume), 
while drag force increases in a linear fashion in laminar flow (e.g., small arteries, 
arterioles or capillaries) [96,99]. This suggests that larger millimeter particles can be 
navigated more efficiently than smaller particles. Additional gradient coils (also referred 
to as steering coils) could be installed in the MRI bore to acquire stronger magnetic 
gradients to navigate smaller particles. Upgraded gradient coils could strengthen the 
magnetic gradients of a 1.5-T clinical scanner from 40 mT/m to up to 400 mT/m [95]. 
The configurational modification allowed efficient steering of microparticles with a 
diameter of 11 𝜇m in a y-shaped microfluidic channel.  
As the SPIONs inside the DEBs can also serve as the contrast agents to guide the 
delivery, simultaneous steering and imaging are possible with a tailored MRI pulse 
sequence. Felfoul et al. designed an MRI pulse sequence that reserved 90% of the 




demonstrated simultaneous steering and tracking of millimeter particles using a vascular 
network phantom. However, this study was lack of clinical relevance as it was conducted 
in the absence of flowing fluid. Further research should include the simulation of 
physiological fluids and tests on animal models to examine the clinical viability of the 
combination of steering and imaging.  
In summary, the validity and efficacy of MRN have been demonstrated in vitro and in 
vivo. MRN provides a promising approach to deliver drugs in a non-invasive and highly 
targeted fashion. In imaging arena, coil configuration, control scheme, and pulse 
sequence must be upgraded for clinical use. In the realm of material science, efforts could 
be made in finding the suitable type and combination of polymers and magnetic 
components to ensure both imageability and targetability.  
2.5.5 Controlled Release  
The drug release profile has huge impact on clinical outcome of TACE. Due to the weak 
association between the drug and oil, Lipiodol emulsions render rapid drug release in vivo 
and quickly elevate plasma drug concentration. This burst release could lead to post-
embolization syndrome and inadequate treatments [101,102].  
In contrast, DEBs allow controlled drug release mainly through two mechanisms: (1) ion 
exchange between the positively charged drug and the same charge ions in the release 
medium and (2) diffusion of the drug through the polymeric network and into the release 
medium. Commercial DEBs including DC BeadTM, HepaSphereTM, Embozene 
TANDEMTM and LifePearl® are made of the ionic polymeric matrix, and the drug release 
typically follows the first mechanism [103]. The second release mechanism is prevalent 
in DEBs composed of non-ionic polymers, such as poly(vinyl alcohol) [104]. For drug 
delivery systems consisted of degradable polymers (e.g., PLGA and chitosan), other 
mechanisms such as erosion/ degradation of the matrix cohabits with the diffusion and 
can dominate over diffusion in many cases [105,106].   
DEBs with controlled release functions could improve safety and efficacy of TACE 




lowering its levels in the systemic circulation. In a phase II clinical trial, DEB-TACE 
group significantly decreased the drug-related systemic and liver toxicity versus the 
cTACE group. In addition, the response rate and disease control rate was higher in the 
DEB-TACE group [31]. 
2.5.6 Degradability 
As suggested by Ha et al., TACE was performed every 6-8 weeks to eradicate tumors 
until thromboses and/or metastases were developed or patients cannot tolerate more 
hepatic damage [107]. Degradable DEBs could be beneficial in TACE to (1) prevent 
extended periods of tumor hypoxia, as it can stimulate the expression of vascular 
endothelial growth factor (VEGF), which adversely promote tumor growth [108], and to 
(2) allow repeat treatments. 
Over the past decade, numerous multifunctional DEBs composed of degradable materials 
were explored (Table 2.5). Such systems are typically composed of hydrogel matrix with 
cleavable linkers that can disintegrate in the presence of acidic hydrolysis, enzyme or 
reactive oxygen species (ROS) environment in vivo [109]. Future work could be 
dedicated to the study of degradation rate, degradation products and the effect of 
degradation on angiogenesis.  





a encapsulation efficiency (%) =
actual amount of DOX in microspheres
mass of feed drug
× 100%      
DOX: Doxorubicin, CMs: chitosan microspheres, ACMs: acetylated CMs, PLGA poly(lactide-co-
glycolide) (PLGA), MSs: microspheres, PEG: poly(ethylene glycol), PEGMA: poly(ethylene glycol) 
methacrylate, N/A: not available.  
2.5.7 Delivery of Multiple Therapeutics 
The co-delivery of multiple therapeutics with complementary modes of action represents 
another future direction for DEBs. TACE leaves the chemotherapy-damaged HCC cells 
under hypoxic conditions, transforming the cancer cells into a more aggressive phenotype 
[110]. Studies have demonstrated the embolization stimulated the expression of VEGF 
that will promote angiogenesis [111]. Systemic administration of antiangiogenic drugs 
such as thalidomide [111], vandetanib [112] and sorafenib/sunitinib (both are antitumoral 
and anti-angiogenetic) [113,114] combined with TACE have demonstrated satisfying 
angiogenesis-suppressing effects in animal models. It is therefore logical to 
locoregionally co-deliver these drugs with anti-tumor agents using DEBs [115]. Forster et 
al. loaded DC BeadTM with several drug combinations and compared their treatment 
safety and efficacy [116]. The co-delivery of two drugs displayed synergistic activity and 
reduced cellular toxicity versus the single-drug loaded DEBs.  Other types of therapeutics 
such as anti-inflammatory agents (e.g., ibuprofen) can be considered as they may reduce 
post-embolization inflammation and pain [117].  
2.6 Design of Multifunctional Materials for Drug 
Delivery 
Science, technology and medicine are continuously looking for new and improved 
treatments for diseases, which tremendously catalyzed research on less toxic, effective 
and cost-effective drug delivery options [118]. The mixing of known materials: 
nanoparticles and hydrogels, offers a simple and effective material strategy to address the 
clinical needs.  
The structural combination of nanoparticles with hydrogels creates a composite platform, 
often referred to as nanocomposite hydrogel or nanoparticle-hydrogel composite [119]. 




components (i.e., nanoparticle and hydrogel) into a single system and enable additional 
functions through the nanoparticle-hydrogel interactions [120].  
Nanocomposite hydrogels can be prepared through four main routes. For the first route, 
nanoparticles are entrapped in the polymeric network by the gelation of hydrogel 
monomers in the presence of preformed NPs [119]. Alternatively, the incorporation of 
NPs can be accomplished after hydrogel gelation by allowing the polymeric network to 
swell and ‘breathe in’ the suspended NPs [121]. Moreover, the NPs could be introduced 
into the gel matrix by loading the hydrogels with the metallic nanoparticle precursors, 
followed by a reduction reaction to form metal NPs [122,123]. Another approach to 
prepare nanocomposite hydrogels is to use NPs as hydrogel crosslinkers (referred to as 
the grafting-onto method in section 2.7.2). Depending on the end groups, the particles are 
anchored in the hydrogels through covalent or non-covalent bonds (e.g., ionic or 
coordination interactions) with the polymeric chains [124,125].  
The properties of the nanocomposite hydrogels are dependent on the innate properties of 
the individual components and particle-hydrogel interactions. As shown in Figure 2.2, 
commonly used nanoparticles and hydrogels with their desirable properties are listed. 
Nanoparticles can bring many unique functions: magnetic responsiveness [99], diagnostic 
imaging [126], electrical conductivity [127], antimicrobial activity [128], and 
compatibility with both hydrophilic and hydrophobic drugs [129]. Hydrogels are known 
for their stimuli-responsive [130], mechanical toughness [131], bioadhesive [132,133] 
and controlled release properties [130]. To satisfy the application requirements, the 





Figure 2.2 Design and processing of a multifunctional hydrogel system for 
biomedical applications. 
The structural and dimensional diversity between the nanocomponents and hydrogels 
provide an effective strategy for the independent delivery of one or more drugs. A 
composite system containing PLGA nanoparticles and hyaluronan (HA)/methylcellulose 
(MC) hydrogel allowed fast drug release from the hydrogel while slow release from the 
nanocarriers [134]. This unique feature was adopted by Zhao et al. to deliver two types of 
drugs independently [135]. The authors achieved dual drug delivery by formulating PTX-
loaded PLGA NPs into temozolomide (TMZ)-loaded hydrogel. The co-delivery of PTX 
and TMZ resulted in a synergistic effect on glioblastoma cells.  In addition to loading one 
drug in hydrogel while the other in nanocarriers, an independent delivery can be achieved 
by incorporating distinct drug-loaded carriers. For example, Patel et al. prepared 
curcumin-encapsulated poly(L-lysine-b-L-phenylalanine) micelles and amphotericin B-
encapsulated poly(L-glutamic acid-b-L-phenylalanine) micelles, separately [136]. 
Hydrogel matrix was created by cross-linking the pendant groups of the polypeptides 
using genipin as a crosslinker. The different pH responsiveness of the two nanocarriers 
permitted independent and switchable release of the corresponding drug. The drug release 




delivery might be helpful in post-surgical cancer management or wound healing, as it 
may provide a synergistic effect.   
The constitution of nanocomposite hydrogels can potentially address the challenges in 
which the nanoparticles or hydrogels are used alone. For example, the incorporation of 
lipophilic nanocarriers can potentially address the incompatibility of hydrogels with 
hydrophobic therapeutics. In turn, the presence of hydrogel can prolong the drug release 
from nanoparticles. Yu et al. utilized lipid nanocarriers to encapsulate a hydrophobic 
drug, quercetin, and reached an encapsulation efficiency greater than 97% [137]. The 
drug-loaded nanoparticles were then physically embedded in a mixture of carboxymethyl 
chitosan (CMCS) and Pluronic® F-127. The resulting delivery system provided a slower 
release rate than that of drug-lipid nanoparticles in the absence of hydrogel. This was 
believed to be contributed by the three-dimensional and water-dense polymeric network, 
which imposed a longer diffusion path and additional diffusion barrier to drug molecules 
[138]. In a comparative study, drug release was performed on two formulations: 
kartogenin (KGN)-loaded halloysite nanotubes (HNT) and KGN-HNT embedded in 
laponite (Lap) hydrogel (KGN-HNT-Lap) [139]. The release kinetics showed that the 
composite formulation greatly prolonged the KGN release compared with KGN-HNT 
system. The authors substantiated that the hydrogel could act as an inert medium to slow 
down KGN release. 
In addition, the nanoparticle and polymeric network interactions can render the composite 
material with unique properties that are not found in individual components. For 
example, Bannerman et al. developed a composite hydrogel comprised of IONPs and 
PVA [140]. The biostable PVA developed degradation behavior under an acidic and iron-
chelating environment. It was believed that the IONPs participated in the cross-linking of 
PVA. As a result, the gradual removal of IONPs would weaken the PVA matrix and 
allowed the degradation to occur. Nasajpour and coworkers fabricated a microfibrous 
membrane of zinc oxide (ZnO) NPs in PCL [141]. It was found that the composite 
membranes degraded faster than plain PCL membranes (pH 7.4 and 8.5). The authors 




which may facilitate water diffusion into the PCL. Moreover, the hydrophilic nature of 
ZnO NPs may also play a role in promoting PCL-water interaction [141].  
Taken together, the combination of nanoparticles with hydrogels provides a 
multifunctional platform for drug delivery applications. Such platform endows function 
integration from each component and can potentially overcome the limitations of 
nanoparticle and hydrogel systems when they are used independently. Moreover, it 
provides an additional degree of freedom in designing or tailoring delivery systems 
through nanoparticle-polymer interactions.  
With the employment of different material processing techniques, the biomedical 
application of nanocomposite hydrogels has gone far beyond what a macroscopic system 
can reach (Figure 2.2). Electrospraying [142], electrospinning [143], microfluidics [144] 
and 3D printing [145] have been used to produce drug delivery systems in the forms of 
fiber, microbead and scaffold. The diversity in the geometry could even expand the 
application spectrum of nanocomposite hydrogels into regenerative medicine and 
multimodal cancer treatments [146–148].  
2.7 Choice of Materials and Proposed Systems 
2.7.1 Poly(vinyl alcohol) 
Poly(vinyl alcohol) (PVA) is one of the most commercially important water-soluble 
thermoplastics in use. It has widespread pharmaceutical and biomedical applications, 
including drug carriers, scaffolds, wound dressing, contact lens and orthopedic implants 
[149]. 
PVA must be stabilized by crosslinking to form a hydrogel before many of its 
applications in biomedical research. Hydrogels are regarded as hydrophilic, crosslinked 
polymeric networks that are able to imbibe larger amounts of fluids and swell when 
placed in water or biological fluids without losing their structure [150].  The crosslinking 




Chemical crosslinking use crosslinkers to form covalent bonds between PVA's secondary 
hydroxyl groups. Commonly used crosslinkers are monoaldehydes (e.g., acetaldehyde 
and formaldehyde),  bifunctional aldehydes (e.g., glutaraldehyde and glyoxal)[151] and 
dicarboxylic acids (e.g., citric acid and maleic acid) [152,153]. The hydroxyl groups of 
PVA react with the crosslinking agents to form intermolecular acetal bridges (bonds) 
where crosslinking could occur [154]. In addition to crosslinkers, sulfuric acid, acetic 
acid or methanol must be used to form the acetal bridges. PVA hydrogel formed by 
chemical crosslinking always retains toxic crosslinkers, which could result in unwanted 
biological effects. The residue of initiators, stabilizers and chain transfer agents could 
also hinder the in vivo application of PVA [155].  
High energy irradiation offers an alternative approach to prepare chemically crosslinked 
PVA. During this process, electron beam or 𝛾 irradiation is used to generate free radicals 
on the polymeric chain. The radicals would subsequently combine through covalent 
bonds to form a crosslinked network. The advantages of this strategy are: no crosslinkers 
are required; no residual impurities; the degree of crosslinking and the pore size of PVA 
gels are tunable by radiation dose and concentration of the polymer solution [156]. The 
limitation with this method is that the radiation exposure may damage the bioactive 
payloads if the crosslinking is performed after the loading [157].  
Physically crosslinked PVA prepared by freezing-thawing technique has generated 
significant interest in biomedical research due to the avoidance of toxic crosslinking 
agents and impurities. In a typical preparation, a homogenous PVA solution is placed 
under repeated freezing and thawing cycles. The gel obtained from such cryogenic 
treatment is often referred to as a cryogel [158]. Phase separation and crystallization are 
the major mechanisms for cryogel formation and impact independently during the freeze-
thaw cycles [159]. The formation of the crosslinked microstructure consists of multiple 
stages. During the freezing process, ice crystals formed within the homogenous PVA 
solution. The water volume expansion and phase separation expel PVA into close contact 
with each other and result in the formation of polymer-rich regions and polymer-poor 
regions. In the polymer-rich regions, PVA chains come into close contact with each 




[159,160]. Repeated freezing processes allow polymer chains to fold into highly 
structured crystallites in PVA-rich regions as network junctions. In thawing stages, ice 
crystals melt, leaving water-filled micrometer-sized pores that make up the polymer-poor 
regions [158].  
A number of process parameters in the preparation could be used to tailor the structure 
and properties of PVA cryogels. These parameters include but are not limited to 
temperature limits of thermal cycling, number of freezing-thawing cycles, polymer 
concentration in the solution and molecular weight of PVA [161]. These parameters 
affect the properties through chain mobility and intermolecular hydrogen bonding, 
resulting in variations in the size and number of crystallites. PVA cryogels with more 
crystalline structures (higher crystallinity) generally display a smaller porosity and higher 
rigidity [155,158].  
Among all the characteristics, the diffusivity of PVA gels attracted particular attention in 
the areas of drug delivery. The porous polymeric network of PVA cryogels, which 
consists of crystalline regions (~3nm) and amorphous regions (~19 nm), regulates the 
transport process of drugs throughout the matrix [158]. The research concluded that the 
diffusion of solutes from hydrogels is related to the mesh size (i.e., the open space 
between polymer chains), which is inversely correlated to crystallinity. Hydrogels with 
higher crystallinity generally have smaller mesh sizes, which would impede the release of 
entrapped macromolecular drugs [162]. Small drug molecules with a dimension smaller 
than the mesh can move freely through the network, while the migration of larger 
molecules such as proteins will be retarded [163,164]. As such, the mesh size can be an 
effective tool for modulating drug loading and controlled release.  
The biodegradation, in contrast to the stability, represents an event where the materials 
degrade, the products become resorbed and disappear via metabolic routes [165]. 
Biodegradable/bioresorbable materials are particularly advantageous to be used for DEBs 
as they allow multiple benefits such as reduced tissue inflammation, controlled drug 
release, and repeatable interventions [166]. PVA-based commercial DEBs: DC Bead® 




provides two effective strategies to make PVA gels degradable. Bannerman et al. 
introduced IONPs to the PVA hydrogels through in situ co-precipitation [140]. IONPs 
were allowed to interact with PVA chains during the subsequent freezing-thawing cycles 
and provide a certain degree of crosslinking to PVA. As a result, the gradual dissolution 
of IONPs in an acidic environment would weaken the linkages and lead to the 
dissolution/degradation of PVA. Another approach to construct degradable PVA 
hydrogels is through blending. PVA has been blended with degradable hydrogels such as 
chitosan [167], sodium alginate [168] and gelatin [150]. As intermolecular hydrogen 
bonding is formed throughout the polymer blends, the degradation of the other polymers 
can unfold the crystal chains and result in PVA dissolution [169,170].  
2.7.2 Iron Oxide Nanoparticles 
Nanotechnologies have emerged as a powerful tool in cancer therapy and the diagnosis of 
diseases [171]. Among all the nanomaterials, iron oxide nanoparticles (IONPs) have 
gained particular interests due to their excellent magnetic properties and biocompatibility. 
IONPs have been extensively investigated for widespread biomedical applications, such 
as magnetic drug targeting, magnetic resonance imaging (MRI), gene therapy and 
hyperthermia/thermal ablation [172]. The most studied IONPs are magnetite (Fe3O4), 
maghemite (𝛾-Fe2O3) and hematite (𝛼-Fe2O3) nanoparticles (NPs).  
IONPs are commonly prepared by two chemical approaches: co-precipitation and thermal 
decomposition. Co-precipitation involves the simultaneous precipitation of ferrous (Fe2+) 
and ferric (Fe3+) ions in an alkaline environment. The mechanism of magnetite NPs 
formation can be described by the following reactions [122]: 
Fe3+ + 3OH− = Fe(OH)3 
 
(1) 
Fe(OH)3 = FeOOH + H2O 
 
(2) 
Fe2+ + 2OH− = Fe(OH)2 
 
(3) 







The overall reaction can be represented by: 
2Fe3+ + Fe2+ + 8OH− = 2Fe(OH)3Fe(OH)2 → Fe3O4 + 4H2O 
 
(5) 
The size, shape and composition of the magnetite NPs can therefore be tuned by altering 
the experimental parameters, including Fe2+/Fe3+ molar ratio [173], pH [122], 
temperature [174], choices of iron precursors (e.g., chloride, sulfate or nitrate) and 
alkaline agents (e.g., NaOH, NH4OH or isopropanolamine) [175–177]. While the co-
precipitation process is the most simple and efficient approach to synthesize IONPs, the 
products often develop a low degree of crystallinity and large size distribution [177].  
In contrast to co-precipitation, thermal decomposition is performed in a non-aqueous 
environment and can better control the size, shape, and polydispersity of IONPs [178]. In 
a thermal decomposition reaction, organic complexes of iron (e.g., iron oleate, iron 
oxyhydroxide or iron pentacarbonyl) decompose at elevated temperatures in the presence 
of non-polar solvents and surfactant capping agents [179]. Surfactants are crucial in this 
process because they modulate the nucleation and growth of the IONPs to ensure good 
mono-dispersity [180]. The concerns with thermal decomposition are high temperatures 
and toxic residuals of the organic chemicals employed [178]. In addition, the non-
hydrolytic nature of the reaction renders IONPs with hydrophobic surfaces, which 
imparts additional modification steps to make water-dispersible and stable IONPs that are 
suitable for biomedical applications [181].  Of note, for both synthesis routes, with the 
addition of oxidizing agents (e.g., HNO3), 𝛾-Fe2O3 or 𝛼-Fe2O3 can be synthesized [182].  
Iron oxide nanoparticles must be endowed with the specific characteristics required for 
targeted biomedical applications. The first and foremost properties are always 
biocompatibility and toxicity [183]. IONPs are generally considered as safe, 
biocompatible and non-toxic materials. The median lethal dose (LD50) of the bare IONPs 
is 300-600 mg/kg body weight. Dextran coating could effectively improve the stability 
and biocompatibility of IONPs and increase this number to 2,000-6,000 mg/kg [184]. 
Due to the broad safety margin of IONPs, a number of surface-coated IONPs have been 
clinically approved as MRI contrast agents, such as ferumoxide, ferumoxtran and 




The biodistribution of IONPs is dependent on the administration route and 
physicochemical factors, such as size, porosity, charge and surface chemistry [186]. For 
intravenously injected IONPs, they are removed from the circulation majorly by the 
mononuclear phagocyte system. It has been reported that IONPs with a hydrodynamic 
size (dH) > 100 nm quickly accumulate in the liver and spleen through macrophage 
phagocytosis. In contrast, particles with dH <10-15 nm are most likely to be eliminated 
through the kidney in a non-phagocytizing pathway [183]. The internalized IONPs are 
metabolized in the lysosomes. The acidic pH environment and intracellular iron chelators 
(e.g., phosphate, nucleotides and dicarboxylic acids) can solubilize IONPs into free irons 
[187]. These irons would subsequently enter the intracellular iron pool and be utilized in 
the production of hemoglobin and transferrin, thereby becoming part of the normal iron 
pool [185]. The excess irons are stored in ferritin or exported by ferroportin, in order to 
maintain the iron concentration within limits to avoid toxicity [188,189]. 
Another crucial property to support the biomedical applications is the magnetic 
properties, particularly superparamagnetism, as it is highly relevant to MRI, hyperthermia 
and magnetic drug targeting. In the presence of a magnetic field, the magnetic moments 
of superparamagnetic materials could align with the direction of the field without any 
remanence magnetization. Fe3O4 and 𝛾-Fe2O3 NPs are the two major superparamagnetic 
iron oxide nanoparticles (SPIONs) employed in research and clinical studies. Their high 
saturation magnetization values (Ms 70-100 emu/g) [190–192] allow generation of large 
magnetic dipoles thereby local magnetic field gradient within the NPs, which will 
strongly alter the spin-spin (i.e., transverse, T2) relaxation times of surrounding water 
protons, resulting an enhanced imaging contrast [88]. Generally, SPIONs (~16-200 nm) 
are used as negative contrast agents for T2-weighted MRI, while smaller (<15 nm) IONPs 
are effective as T1 (i.e., positive) contrast agents [193]. In addition, the relatively high Ms 
values of SPIONs would also allow precise spatial control over the particles in the blood 
using an external magnetic field generated by a magnet or MRI coil. This activity has 
been translated into magnetic drug targeting and MRN, as described in section 2.5.4. The 





Moreover, SPIONs can respond to an alternating magnetic field and convert the magnetic 
energy to heat within the particles. The heat generated can be used to elevate the 
temperature of the surrounding tissue. The effectiveness of hyperthermia relies on the 
fact that a temperature between 41-43 °C can cause tumor cell death, as they are less 
tolerant to heat than normal cells [195,196]. In hyperthermia treatments, SPIONs can be 
administered intravenously or intratumorally. Particle concentration should be large 
enough to deliver a sufficient heating effect.  
Despite the great potential of IONPs in diagnostic imaging and drug delivery, the 
limitations with using such particles as an individual delivery system are also obvious: 
poor colloidal stability, short blood circulation, burst release, limited drug loading 
capacity, plasma protein adsorption, and unregulated biodistribution and 
pharmacokinetics [183].  
To address these limitations and further expand the applications of IONPs, a composite 
platform named ferrogel (i.e., the combination of hydrogels with IONPs) was developed 
[197]. Ferrogels can be prepared mainly via three routes: blending, in situ co-
precipitation, and grafting-onto. They can be further classified into polymer-first (in situ 
co-precipitation) and particle-first (blending and grafting-onto) approaches [198]. The 
scheme for the three approaches is shown in Figure 2.3. Depending on the choice of 
materials and the preparation methods, IONPs can form different interactions with the 
hydrogel matrix. The blending method consists of a sequential preparation, where IONPs 
are synthesized separately and added to a hydrogel precursor solution. The mixture is 
then stabilized by the crosslinking of the hydrogel. While being facile, the blending 
method fails to achieve a uniform nanoparticle distribution within the polymeric network. 
Moreover, particles remain attached mainly through physical entanglement and hydrogen 
bonding with the polymer chains [199]. Due to the limited particle-hydrogel interactions, 
IONPs might diffuse out from the hydrogel upon swelling [200]. In the in situ co-
precipitation process, the hydrogel matrix acts as the reactor. In detail, hydrogels are 
firstly crosslinked through chemical or physical routes. The IONP precursors (Fe2+ and 
Fe3+) are prepared in a stoichiometric ratio and mixed with the crosslinked hydrogel to 




solution for the IONPs to precipitate. The mechanism with which IONPs are immobilized 
in the gel was not fully elucidated. However, it is believed that the IONPs participate in 
the polymeric network formation through hydrogen bonding with the hydrogel chains 
[140,201,202]. In situ co-precipitation provides improved IONP dispersion in the 
hydrogels. However, this method is limited to alkali-resistant polymers and should also 
be avoided in hydrogel systems containing bioactive compounds, such as proteins and 
cells, as the harsh environment may damage their bioactivity [203]. Compared to 
blending and in situ precipitation methods, the grafting-onto approach provides particle-
hydrogel interactions through covalent bonds in addition to hydrogen bonds and van der 
Waals forces [204]. In the grafting-onto method, IONPs serve as the crosslinkers to the 
hydrogel monomers. In detail, IONPs are initially functionalized with reactive moieties 
(e.g., -NH2 and -COOH). The nanoparticles are then added into a monomer solution to 
form covalent bonds with the monomers when polymerized. As the IONPs are covalently 
bonded to the network, the stability of ferrogel is guaranteed [125]. In the future, the 
grafting-onto method would benefit from research efforts in simplifying the preparation 
cycle and fabrication process [200].  
 
Figure 2.3 Schematic of ferrogel preparation. (A) The blending method. (B) The in 
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Overall, IONPs have been helpful in the development of multimodal therapeutic 
strategies, enabling a simultaneous exertion of therapeutic effect, hyperthermia and 
diagnostic imaging. Further research could focus on the development of self-healing 
materials and magnetically sensitive smart hydrogels [203]. Despite the wide range of 
applications, the cytotoxicity and long-term fate of magnetic materials, including 
individual particles and ferrogels, have yet to be fully revealed. As such, in vivo studies 
using animal models should be continued to supplement in vitro findings.  
2.7.3 Silica Particles 
Considerable research efforts have been made in developing silicate materials for 
biomedical applications. Silica (also known as silicon dioxide, SiO2) has been "generally 
recognized as safe" by the FDA for more than five decades and is widely used in the food 
industry as a color or formulation stabilizer [205,206]. Among all types of silica, SiNPs 
plays a particularly critical role in fulfilling the rigorous clinical requirements for disease 
diagnosis and controlled drug release. The presence of abundant surface silanols (Si-OH) 
allows the conjugation of various organic functional groups, rendering SiNPs with a high 
level of versatility for drug delivery applications [207]. 
SiNPs are predominantly synthesized via the sol-gel process. Both hydrolysis and 
condensation can be acid- or base-catalyzed. Sol-gel process typically involves the 
hydrolysis and condensation of alkoxide precursors [e.g., Si(OC2H5)4 or TEOS] in the 
presence of alcohols (e.g., ethanol), water and catalysts (e.g., NaOH or HCl). The 
simplified reactions that form SiNPs can be represented by [208]:  
Hydrolysis: Si-(OR)4 + H2O ⇌ HO-Si-(OR)3 + ROH 
 
(6) 
Condensation: (OR)3-Si-OH + HO-Si-(OR)3 ⇌ (OR)3-Si-O-Si-(OR)3 + H2O 
 
(7) 
where R=alkyl group 
The reaction forms a discrete, colloidal suspension (i.e., sol). The colloidal particles (1-
100 nm) within the sol then condense to form an interconnected, rigid network with pores 
and polymeric chains (i.e., gel). The viscosity of the solution increases sharply at gelation 




of the sol-gel process is profoundly affected by the rate of hydrolysis and condensation 
reaction [210]. In an acidic environment, hydrolysis is slow. The silica tends to form a 
linear, weakly crosslinked network. Gelation proceeds by the formation of additional 
branches and the entanglement of polymeric chains. As a result, acid-catalyzed sol-gel 
generally leads to a gel structure [211]. In contrast, hydrolysis and condensation are fast 
in the basic-catalyzed process [208]. This results in the rapid formation of highly 
branched and non-interpenetrable clusters [209].  The clusters collide and lead to larger 
aggregates through hydrogen bonding and van der Waals interactions. At a critical 
concentration, the aggregates will precipitate in the form of discrete species as SiNPs 
[210]. Various mechanical (e.g., centrifugation) and physical (e.g., oven drying and 
alcohol dehydration) techniques can accelerate the water removal hence the formation of 
SiNPs [211].  
As the pH conditions lead to silica networks with distinct properties, it is not surprising to 
see that each catalytic condition has its own characteristic applications. Acid-based sol-
gel synthesis is predominately utilized in the development of nanocomposite hydrogels. 
Namely, the reaction occurs in the presence of hydrogels to form SiNPs-embedded 
hydrogels. The relatively slow hydrolysis step would result in molecular chains contain 
sufficient silanol groups to participate in hydrogen bonding with the hydrogel polymers 
[209]. The formation of SiNPs-hydrogel interaction affects the intramolecular bonding of 
the polymeric chains; therefore could help modify the mechanical properties and 
permeability of the gels [212–214]. For example, a silica/PVA composite hydrogel was 
prepared by in situ sol-gel synthesis [213]. SiNPs possessed good dispersion in the 
hydrogel matrix and developed strong interaction with PVA through Si-O-C bonds. 
Results showed that SiNPs served as a stiffness enhancer to PVA. A greater mass 
percentage of SiNPs in the PVA increased Young's modulus by up to ~14 folds. 
Similarly, silica/PVA nanocomposite hydrogel was prepared and electrospun into 
nanofibers [215]. The author found that the in situ formation of SiNPs contributed to the 
crosslinking of PVA, which reduced the -OH available for hydrogen bonding with water. 




Base-catalyzed mechanism is widely employed in the preparation of discrete SiNPs. Such 
a process is considered simple, fast and allows precise size and morphology control 
[216]. Stöber and Fink pioneered this approach in synthesizing non-porous silica spheres 
in the range of 50-2000 nm [217]. The authors found that particle size was dependent on 
the type of alcoholic solvents, silica precursors, and the concentration of water and 
ammonium hydroxide. The resulting non-porous silica particles are extensively used as 
hydrogel nanofillers [218], stabilizing agents [205,206] and matrix for protein adsorption 
study [219]. The applications of non-porous silica particles have been extended into drug 
carriers after surface modification with appropriate functional groups [220].  
Base-catalyzed sol-gel process has also been adopted to prepare mesoporous SiNPs (i.e., 
SiNPs with pores sizes in the range of 2-50 nm) [221,222]. Amphiphilic copolymers or 
cationic surfactants are essential in the synthesis of porous SiNPs, as they serve as pore 
template and determine pore size. Templates with longer chain lengths typically result in 
larger pores [223]. As the drug transportation within non-functionalized porous SiNPs is 
through diffusion, the pore size and volume must be carefully designed to modulate the 
payload loading and release. Greater pore size and volume generally result in larger 
loading and faster release than particles with smaller pores [224]. This could be explained 
by the steric hindrance effects inside the mesopores [225]. Mesoporous SiNPs with extra-
large pores (~25 nm) are extremely helpful in the loading and release of proteins, 
enzymes and DNA vaccines [223,226,227]. 
Sol-gel SiNPs, either in porous or non-porous form, are semicrystalline material and 
susceptible to hydrolytic attack, which encourages the degradation and clearance of 
SiNPs in vivo. The degradation process contains multiple stages: hydration, hydrolysis 
and ion exchange. The silica framework will eventually be converted to silicic acid 
(Si(OH)4, pKa 9.6), a water-soluble compound [228]. The rate of dissolution is largely 
dependent on the physicochemical properties of the particles [229], pH [230] and 
composition of the dissolution media [231]. Silicic acid is non-toxic and has a natural 
promoting effect on bone mineral density [232]. The degradation product can diffuse 
through the bloodstream or the lymphatic system. The ultimate excretion is through urine 




In conclusion, SiNPs have gained growing interests as an advanced platform for 
biomedical applications. For future directions, more studies are expected in the 
evaluation of the toxicity, biological stability, and efficacy of SiNP-based delivery 
systems. Innovations could be made in designing targeted, stimuli-responsive platforms 
for gene and vaccine delivery [234]. 
2.7.4 Proposed Systems 
This thesis covers three multifunctional delivery systems. The research work of Chapter 3 
and Chapter 5 is based on composite hydrogel microparticles, while Chapter 4 contains 
work on the silica nanoparticles.  
Chapter 3 PVA-IONP microparticles 
Chapter 3 describes a multifunctional ‘nano-on-micro’ drug delivery system. Figure 2.4 
shows the composition of the system. In detail, magnetite (Fe3O4) nanoparticles were 
immobilized in the PVA matrix via in situ co-precipitation followed by freezing-thawing 
process. The targeted particle size is 100-300 𝜇m, as the beads in this size range are 
preferred in clinics due to the effective local necrosis and less systemic complications 
compared to larger ones [62–64]. 
 
Figure 2.4 Schematic drawing of a multifunctional PVA-IONP microparticle. 
The PVA-IONP microbeads are promising candidates for embolic DEBs in TACE 




ability to embolized tumor-supplying vessels; drug loading and controlled release 
capacities; the co-localization of drug with contrast agent; the potential for targeted drug 
delivery through image-guided magnetic resonance navigation (MRN) of the 
superparamagnetic microparticles; the possibility for repeatable TACE treatments, as the 
degradation of microbeads can occur with the dissolution of IONPs and the disintegration 
of PVA matrix. 
Chapter 4 SiO2 nanoparticles 
The protein delivery system is based on non-porous SiNPs, as shown in Figure 2.5. 
SiNPs were synthesized by Stöber process and loaded with bioactive proteins via 
adsorption. SiNPs interact with proteins through hydrogen bonding and electrostatic 
interactions. The targeted size of the protein carrier is 100-400 nm, as it can provide a 
reasonable residence time on the ocular surface [235–237]. Such delivery system can 
potentially fulfill several roles: protection from protein decomposition, sustained release 
and tunable release profile. The system is hypothesized to be helpful in topical delivery 
of protein therapeutics to treat dry eye disease by reducing the dosing frequency and 
allowing personalized drug dosage.  
 






Chapter 5 PVA-SiO2-IONP microparticles 
The formulation described in this chapter is a continuation and optimization of the PVA-
IONP system. The multifunctional drug carrier in Chapter 5 is comprised of a PVA 
matrix, loaded with IONPs and SiO2 microparticles (Figure 2.6). Similar to the PVA-
IONP system, PVA-SiO2-IONP microparticles are anticipated to be beneficial for 
application as DEBs for TACE treatment.  
 
Figure 2.6 Schematic drawing of a multifunctional PVA-SiO2-IONP microparticle. 
2.8 System Assembly using Microfluidics 
Microfluidics will be used to produce our microparticulate multifunctional drug carriers. 
The materials and fabrication techniques for microfluidic chips, droplet generation 
mechanisms, and channel configurations will be reviewed in this section. The advantages 
of using microfluidics in fabricating drug delivery systems will also be discussed. The 
detailed fabrication approach will be described in Chapter 3 and Chapter 5. 
2.8.1 Materials and Fabrication Techniques for Microfluidic Chips 
Poly(dimethylsiloxane) (PDMS) is the most common microfluidic material employed in 
research laboratories due to its convenient fabrication by soft lithography and reasonable 
cost [238]. Devices with 3D structures or multilayers can be prepared via curing 
individual pieces at mild temperatures (40-70 °C) and stacking [239]. The ability to 




(e.g., biological interactions, cell sorting, bioanalysis and diagnostics) [240–242]. 
However, the alkyl groups attached to PDMS’s Si-O backbone lead to nonspecific 
adsorption and swelling. More specifically, hydrophobic molecules and biomolecules 
could adhere to channel walls and lead to channel clogging and inaccuracy in the 
measurements [243,244]. Another drawback is the incompatibility with organic solvents 
[245]. Upon exposure to organic solvents such as acetone, swelling of the channel would 
affect droplet generation and device deformation [246]. Surface modifications of the 
PDMS with hydrophilic moieties can address these issues, but the challenges arose in 
maintaining the long-term stability and hydrophilicity of the modified surface [247,248].  
PMMA has gained interests as an alternative to PDMS. PMMA is particularly useful for 
disposable chips because of its fairly good rigidity, chemical resistance, transparency and 
biocompatibility [249].  In general, PMMA microfluidic microdevices consist of channel 
plates and cover plates that need to be sealed together. The channel plate can be created 
using a wide range of techniques [250], including hot embossing, laser ablation, 
imprinting, molding and solvent etching, making them desirable for mass manufacturing. 
However, creating uniform surface bonding of the two plates without deforming the 
channel structure represents a significant barrier for industrial fabrication. A number of 
approaches have been explored: thermal, solvent, adhesive, or polymerization bonding 
have demonstrated robust bonding [250]. Similar to PDMS, biocompatible PMMA 
microdevices with predefined geometry are extremely useful in bio-related fields. 
However, the hydrophobic nature of PMMA resulted in nonspecific adsorption and poor 
wetting properties at the channel wall. To overcome these challenges, various surface 
modification [251] and bulk modification [252] methods been developed. 
Hydrogel is another class of material that can be used to make microfluidics. Chips made 
from hydrogels have particular interests in biological applications and biomimicking due 
to their similarity with extracellular matrix (ECM). The porous, 3D and water-rich 
polymeric environment allows the diffusion of cell nutrients and growth factors, making 
it a promising substrate for cell culture and encapsulation [253]. Gel-based microfluidic 
devices can be fabricated by soft lithography, flow solidification and gel 




resolution in microfabrication (micrometer scale) compared with other polymers 
(nanometer scale), (2) limited capacity supporting thick layer cell culture, (3) channel 
sealing (surface bonding) is difficult [254–256]. Efforts in exploring alternative 
micropatterning and integrative methods as well as materials could possibly address these 
challenges in the future.  
Inorganic materials, including silicon and glass have been used for microchips even 
before the concept of 'microfluidics' has emerged. Silicon and glass microfluidic channels 
are typically made by photolithography and chemical etching [257]. Due to their good 
thermostability and solvent resistance, silicon/glass microdevices become a key platform 
for lab-on-chip design, droplet generation and bio-separation [258]. The drawbacks with 
such devices are associated with the sealing of the two plates and the relatively expensive 
and time-consuming fabrication process [257,259]. A picosecond pulsed laser system has 
been adopted and demonstrated feasibility in addressing the issues mentioned above 
[259].  
2.8.2 Droplets Generation Mechanisms 
Droplet microfluidics (or droplet-based microfluidics) is a subdivision of microfluidics 
that aims at producing and manipulating individual droplets. The generation of slugs or 
discrete volumes in microchannels replies upon immiscible multiphases [260]. A 
continuous phase is referred to the liquid in which droplets flow, while a dispersed phase 
is the droplet phase. 
The mechanisms of droplet formation have been studied in depth. Reynolds number (Re) 
is the dimensionless parameter in fluid mechanics used to predict flow patterns [261]. It 






where 𝜌 is the density of the fluid, D is the diameter of the passageway, 𝜈 is the velocity 
of the liquid, and 𝜇 is the viscosity of the liquid. Laminar flow represents a flow with 
parallel streamlines without disruption. Turbulent flow characterizes non-linear, irregular 




turbulent flows is marked by Re of ~1,800-2,000 [263]. As the diameter D and velocity 𝜈 
are relatively small for the fluids in the microchannels, droplet microfluidics typically 
falls in a low Reynolds number (usually much less than 100, often less than 1.0) laminar 
regime [264,265]. As such, inertial effects in the flow are negligible-the flow is 
dominated by viscous stresses [265].  
In a microfluidic device, the confinement of the channels enhances the surface-to-volume 
ratio of the fluids, which consequently leads to the enhancement of surface tension and 
fluid viscous force [264].  The negligible inertial effects leave interfacial tension and 
viscosity in competition with each other [266]. When the two immiscible phases were 
introduced together, the continuous phase disrupts the dispersed phase due to the viscous 
forces. The mixing would introduce nonlinearity and instability at the junction of two 
microchannels where the dispersed phase would break into droplets or plugs due the 
tendency of surface tension to minimize the interfacial area [267,268].  






where 𝜇 is the viscosity of the continuous phase, 𝜐 is the superficial velocity of the 
continuous phase, and 𝛾 is the interfacial tension or surface tension between the two 
fluidic phases. At low capillary numbers, surface tension dominates, and the droplets 
remain spherical (dripping model). As the Ca increases, viscous forces increase. The 
shear stress applied to the droplet is large enough to overcome the surface tension. The 
initially spherical droplet becomes ellipsoidal plugs and eventually breaks into smaller 
droplets further downstream (jetting model) [269–271]. The balance of the two forces 
determines the flow pattern whether droplets (dripping) or plugs (jetting) form under a 
given condition. In general, droplets generated in dripping regimes are smaller in 
diameter with narrower size distribution [271,272]. As such, the dripping mode is 




2.8.3 Geometrical Design of Microchannels 
The droplet generation mechanisms are adapted to guide the microparticles fabrication. 
Both passive and active techniques can be used to produce uniform and evenly 
distributed droplet volumes ranging from femtoliters to nanoliters. In active droplet 
production, microchannels in predesigned configurations are required to enhance the 
viscous shear force to secure the continuous formation of droplets.  
Three primary microfluidic channel geometries are used: co-flow, T-junction and flow-
focusing (Figure 2.7). In a co-flow geometry, also called coaxial flow, a cylindrical glass 
capillary is coaxially inserted into square glass tubes. The dispersed phase flows in the 
capillary in parallel to the continuous phase placed in a larger-diameter glass tube. The 
continuous phase surrounds the dispersed phase, and the droplets are generated mainly by 
the instability of the dispersed phase due to surface tension (Rayleigh-Plateau instability) 
[268]. The size of droplets can be tuned by the fluid properties and flow rates [271]. The 
cylindrical geometry of the center capillary limits the geometry of co-flow devices to a 
3D architecture. In contrast, the T-junction and flow-focusing are applicable in planar 
geometries but possess more complicated droplet breakup mechanisms [266]. T-junction 
design is a subdivision of cross-flow designs, where the dispersed phase is sheared at an 
angle θ (0° < θ < 180°). In the T-junction category, the dispersed and continuous phase 
flow in orthogonal channels meet at a cross-junction. The viscosity of two fluids, 
interfacial tension and channel geometries can affect the droplet formation [273]. The 
flow-focusing design is similar to co-flow. The continuous streams flow on both sides of 
the dispersed phase to a focus unit, where the three streams are forced through in a 
condensed passageway. The extended pressure and shear stress generated by the 
continuous phase breaks the dispersed phase inside or downstream of the orifice [274]. 
The droplet size can be controlled by the viscosity of the two phases, flow rates and inlet 
pressure [275]. In general, passive technique allows the coefficient of variation (CV), 
defined as the standard deviation in size divided by the mean droplet diameter, to remain 





Figure 2.7 Schematic illustration of different channel geometries of a microfluidic 
device. (A) Co-flow; (B) T-junction; and (C) flow-focusing. Solid arrows indicate the 
flow direction. 
Active methods implement external forces to exert local actuation to break up the fluid 
stream physically. The co-flow, T-junction and flow-focusing channel geometries still 
apply, and additional pneumatic, acoustic forces and magnetic forces are introduced to 
produce droplets on demand [277]. Active mixing purposely creates chaotic motion in the 
device, which promotes mass transfer. This expands the application of microfluidics into 
bioreactors for cells or bacteria since it accommodates fast and adequate oxygen and 
nutrients transfer [278]. 
2.8.4 Droplet Microfluidics in Drug Delivery 
Droplet-based microfluidics enables precise and reproducible production of micro- or 
nanocarriers as drug delivery systems. This technique renders several advantages over 
conventional bulk production, including tailored particle size and encapsulation of 
various types of drugs. 
Tailor microparticle size to tumor arterial anatomy 
DEB size is one of the key parameters that would affect the procedure outcome. Animal 
studies have suggested that smaller size DEBs (70-150 𝜇m) had deeper tissue penetration 
and greater drug coverage (i.e. amount of tissue exposed to drug) than the beads in the 
standard size range (100-300 𝜇m) [279]. Eddy and Casarett claimed that tumor vessels 
maintained a capillary-like structure. Capillaries are typically less than 12 𝜇m in 
diameter, and some vessels that could progressively dilated and reached diameters ~200 
𝜇m based on their studies on the hamster [280].  It has been advised that the human 
tumor blood vessels were much larger in diameter than what would be predicted based on 




animal models [281]. Moreover, the diameter of tumor is also histology- and location-
dependent [18]. These variants in tumor vasculature suggest that providing DEBs in 
several size ranges is necessary. 
Microfluidic fabrication allows reproducible fabrication of particles of size over a broad 
size range (10-1000 𝜇m). Particles of different sizes can be simply prepared by tuning the 
flow rates or properties of the dispersed phase or continuous phase [282,283]. The 
particles are highly uniform in size with CV < 3% [276]. Microparticles in defined 
geometry could be advantageous in DEB application, as they can provide predictable 
drug eluting profile and embolization outcome.  
Encapsulation of various types of drugs 
In microfluidics, drug molecules could be encapsulated into the carriers through single 
emulsions, multiple emulsions or hierarchical porous particles. For single emulsion 
templated particles, drugs can be suspended in a dispersed phase and encapsulated into 
the particles through forming oil (O)-in water (W) or W/O emulsions [284,285]. For 
double emulsion systems, W/O/W configuration is typically used. Drugs are encapsulated 
in the internal water phase of the double emulsion and can improve the stability and 
solubility of the drugs [286,287]. In addition to encapsulation, porous nanoparticles-in-
microcarriers provide another approach for high drug loading via physical adsorption at 
pore surfaces [288,289].  
Microfluidics techniques expand the material selection and ease the loading of drugs with 
various properties. In conventional preparation of delivery systems, hydrophilic drugs are 
generally loaded into hydrogel particles [106], while lipophilic drugs are mostly limited 
to liposomes and solid lipid nanoparticles [290]. With the aid of microfluidic techniques, 
both hydrophilic and lipophilic payloads can be encapsulated into the delivery vehicles 
[144]. Multiple drugs loading can be realized by microfluidic fabrication of 
microparticles with multiple compartments for separate encapsulation of drugs. For 
example, core-shell particles were prepared via double emulsion templates, hydrophilic 
therapeutics DOX was loaded into gelatin methacryloyl (GelMA) cores, while 




Similarly, Winkler et al. prepared Janus particles for simultaneous delivery of a 
hydrophilic-hydrophobic drug pair. Acetaminophen (APAP, hydrophilic) was entrapped 
in inner water droplets within an oil phase containing naproxen (NPX, hydrophobic), the 
W/O emulsion was then stabilized in another aqueous solution to form a W/O/W 
emulsion [292]. He et al. fabricated dual-/triple-compartmental microparticles using a 
novel W/W template [293]. Each compartment is a W/W droplet consist of calcium 
alginate (Ca-Alg) as the shell material and sodium carboxymethylcellulose (CMC) as the 
inner fluids. The compartments were aligned by needles and then fixed via Ca2+ 
crosslinking in the outer layer of Ca-Alg. The dual compartments in the resultant capsules 
were used separately to load two distinct model drugs.  
2.9 Clinical Applications and Future Translational 
Opportunities 
Multifunctional microparticles offered several improvements to the current DEBs (Table 
2.6). Namely, the prepared system could be delivered through a catheter or even MRN. 
The co-localization of contrast agent and drug allows a more precise tracking of the drug 
distribution relative to the tumor site through MR imaging. This would provide useful 
information for intra- and post-procedural evaluation of the TACE procedure. Moreover, 
the delivery system can potentially render a controlled drug release to maintain an 
effective local drug dosage. The IONPs and silica particles participate in the crosslinking 
of PVA and render additional functionality through the particle-PVA interactions. More 
specifically, the composite hydrogel would disintegrate as the IONPs and (or) silica 
dissolve, which would allow the elimination from the embolization site with due course 
of time, which would allow repeatable TACE treatments. Besides, one or more drugs can 
be possibly loaded. In addition to treating the intermediate HCC, multifunctional 







Table 2.6 Comparison of current DEBs with multifunctional microparticles. 
 
New polymeric platforms must be developed to allow the integration of multiple 
desirable functions described in section 2.5. The development of novel material strategies 
will also expand the drugs amendable to hydrogel-based systems. A combinational 
treatment regimen might be possible with a wide range of functional particles and 
bioactive molecules becoming compatible with the DEBs. Several microparticulate 
platforms have demonstrated the viability for combined regimens, including 
hyperthermia-TACE [295] and stem cell therapy-chemotherapy [296]. These may 
improve the clinical outcome of the treatments.  
Multifunctional nanoparticles provide protection and sustained availability to therapeutics 
compared to free dosage forms. Improvements could be made through surface 
functionalization and introducing porous structure [211]. Nanocarriers can be used alone 
or incorporated into existing platforms, such as hydrogels or contact lenses to construct 
drug-eluting medical devices. Future studies on the safety and effectiveness must be 
warranted to validate their potential benefits. 
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Chapter 3  
3 Development of Multifunctional PVA-IONP 
Microparticles for TACE1 
3.1 Introduction 
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the third 
most common cause of cancer-related death [1]. Potentially curative treatments, including 
liver transplantation, surgical resection, or radiofrequency ablation, are reserved for 
patients with early-stage HCC. However, 50% of patients with HCC are diagnosed at 
intermediate or advanced stages due to the poor prognosis, precluding curative-intent 
options [2]. 
Transarterial chemoembolization (TACE) plays a vital role in the clinical management of 
HCC. According to the most frequently used BCLC algorithm for HCC, TACE is 
recognized as first-line therapy for patients with multinodular HCC and preserved liver 
function (BCLC stage B) [3,4]. Besides, TACE is commonly recommended as the 
bridging therapy to downstage patients waiting for liver transplantation [5]. The role of 
TACE in HCC management continues to evolve, as TACE was evidenced to be an 
effective option in managing recurrent HCC after curative treatments [6,7].  
TACE combines transarterial embolization (TAE) with the infusion of 
chemotherapeutics. It can be performed through conventional TACE (cTACE) and drug-
eluting beads TACE (DEB-TACE). cTACE involves the catheter-guided delivery of 
antineoplastic drugs using Lipiodol-based emulsion, followed by administration of 
embolic agents to achieve a synergistic effect of drug cytotoxicity and ischemia [8]. For 
DEB-TACE, embolic particles are loaded with anti-tumor drugs before their transarterial 
administration. As such, a simultaneous exertion of both therapeutic and embolic effects 
can be possible. Although clear evidence of the superiority of DEB-TACE over cTACE 
 
1
 A version of this chapter will be submitted to Polymers under the title: Development of multifunctional 
poly(vinyl alcohol) hydrogel microparticles for transarterial chemoembolization therapy. Xinyi Li will be 




is yet to be found, the former technique offers a favorable pharmacokinetic profile with 
an improved loading capacity and release profile, along with a more standardized and 
repeatable hospital protocol [9–12]. 
The most commonly used commercial DEBs are DC BeadTM (Biocompatibles, United 
Kingdom) and HepaSphereTM (BioSphere Medical, France), Embozene TandemTM 
(Varian Medical Systems, United States) and LifePearl® (Terumo International Systems, 
Belgium). These products are non-degradable, making repeat treatment impossible. Also, 
imaging contrast agents have to be administered separately, leaving the location of the 
beads and therefore the anti-tumor drugs rather imprecise. 
Over the past decade, there has been a growing interest in designing magnetic and 
degradable DEBs. Magnetic characteristic allows post-operational evaluation of particle 
biodistribution and tumour response. Superparamagetism would be preferred as it permits 
magnetic resonance imaging (MRI)-guided TACE. Degradable DEBs could address the 
concerns of non-target embolization, ischemia-induced angiogenesis, and allow 
repeatable treatments [13,14]. In addition, the integration of multiple functions, including 
embolization, imageability, controlled release and degradation, would ideally permit a 
safer, more effective and repeatable TACE treatment.  
 
Physically crosslinked PVA hydrogel prepared using the low temperature thermal cycling 
(LTTC) process has many desirable properties for DEB-TACE therapy [15]. However, 
PVA hydrogel is known to be biostable and nondegradable. Our prior work demonstrated 
that it is possible to design a ‘degradable’ PVA hydrogel with incorporated iron oxide 
nanoparticles (IONPs) using the LTTC process. In this composite system, IONPs 
contribute to the crosslinking of the PVA-IONP hydrogel. Since IONPs can degrade and 
become soluble under physiological conditions and the slightly acidic tumor 
environment, the composite hydrogel would ‘degrade’ via removal of the crosslinks and 
redissolution [16]. The anti-cancer drug, doxorubicin (DOX), can be loaded into this 





In this work, we first fabricated iron-containing PVA hydrogels in the form of 
microbeads using the microfluidic technique. Superparamagnetic iron oxide nanoparticles 
were formed and anchored into the microbeads through in situ co-precipitation and LTTC 
process. The morphological and structural characteristics of the resulting PVA-IONP 
microparticles were examined by electron microscopy. The magnetic properties, MRI 
contrast effect, and degradation were evaluated. Finally, DOX loading and in vitro 
release were studied in simulated healthy tissue and tumorous conditions. PVA-IONP 
microparticles obtained can successfully integrate multiple functions into a single system, 
therefore it could be promising to be used as DEBs for TACE. 
3.2 Materials and Methods 
3.2.1 Materials 
Poly(vinyl alcohol) (MW 146,000-186,000, 99+% hydrolyzed), iron (III) chloride 
(FeCl3), iron (II) chloride tetrahydrate (FeCl2∙4H2O) and phosphate-buffered saline were 
purchased from Sigma-Aldrich, sodium hydroxide (NaOH) pellets and Dulbecco’s 
modified Eagle’s medium (DMEM) were obtained from ThermoFisher Scientific. 
Hydrochloric acid (36.5%-38%) was acquired from Caledon. Span80 was obtained from 
Fluka. Doxorubicin hydrochloride was purchased from Cayman Chemicals. Phosphate 
buffer solution (pH 5.5) was prepared by a procedure reported elsewhere [17]. The rest of 
the chemicals were all in ACS reagent grade and purchased from Sigma-Aldrich. 
3.2.2 Assembly of the Microfluidic Device 
A planar microchannel was milled out of a poly(methyl methacrylate) (PMMA) slab (50 
x 25 x 12 mm) with a flow-focusing configuration. The continuous phase flow channel 
dimensions were about 500 m in width, while the measured channel dimensions for the 
dispersed phase were about 200 m. A second PMMA slab (50 x 25 x 12 mm) was 
sealed onto the slab containing channels by screws. Liquids were supplied to the 
microfluidic channel separately using two syringe pumps (NE-1000, New Era Pump 
Systems Inc.). A 0.038” outer diameter tubing (Intramedic polyethylene tubing, BD) was 




3.2.3 Preparation of Dispersed Phase 
Dispersed phase containing IONP precursors were prepared as described elsewhere [16]. 
Briefly, a 5.88 wt.% PVA stock solution was prepared by dissolving PVA powder in a 
reactor at 90°C for 3 hours. Iron chloride solution was prepared by dissolving 6.20 g 
FeCl3 and 3.80 g FeCl2•4H2O in 20 mL distilled water. The iron solution and PVA 
solution were then mixed proportionally to make a final mixture containing 5 wt.% PVA, 
1 wt.% FeCl3 and 0.6 wt.% FeCl2•4H2O. The resultant mixture was filtered through a 
5μm filter (Acrodisc® syringe filter, Pall Laboratory) and used as the dispersed phase. 
3.2.4 Microfluidic Fabrication of Microparticles 
Undecane containing 1 wt.% Span80 was used as the continuous phase. The flow rate of 
the continuous phase was set at 20 mL/h, while the dispersed phase flow rate was kept at 
1 mL/h. The continuous phase was flushed through the microfluidic device for at least 30 
seconds to convert the microchannel wall to completely hydrophobic. Droplets were 
collected after a steady state was reached (~5min). A high-speed camera (Redlake 
MotionScope M with a frame rate up to 1000 frames/sec) was used to image the beads 
formation process.  
The microdroplets generated were subsequently guided to a container containing 0.5 
mol/L sodium hydroxide (NaOH) solution, whereby IONPs formed and the droplets 
solidified. The resulting microbeads were further collected and washed with 50v/v% 
ethanol in water several times and subject to six freeze-thaw cycles (FTCs) (from 20°C to 
-20°C then to 20°C at 0.1°C/min, held for one hour at the temperature limits). After that, 
the microbeads were stored in phosphate-buffered saline (PBS) at room temperature until 
future use. 
3.2.5 Microscopy Observation 
Morphological observation and size analysis were first acquired from an optical 
microscope (Olympus BX60) equipped with an OMRX A35100U camera. Samples were 
prepared by dropping microbeads suspension on the microscope glass slides. The area of 




Appendix A for an image used in this measurement) and then converted into an 
equivalent spherical diameter using the following equation:  
d = 2√A/π 
 
(1) 
where d is the equivalent spherical diameter and A is the measured sectional area of the 
microbead. 
Surface morphology was examined with a scanning electron microscope (SEM, LEO 
(Zeiss) 1540XB FIB/SEM). Microbeads were dehydrated through to 100% ethanol by 
incrementally increasing ethanol concentration. Critical point drying (Samdri PVT-3B) 
was performed on the microbeads loaded onto a p-type silicon wafer with 0-10 Ohm-cm 
resistivity and orientation of 100 (University Wafers). Before imaging, samples were 
sputtered with a 5 nm osmium coating (Plasma Coater, Filgen). EDX was also performed 
on these samples for elemental analysis. 
Transmission electron microscopy (TEM, PhillipsCM10) was performed to reveal the 
beads' microstructure and acquire the size and shape of internal IONPs. TEM samples 
were prepared by dropping the microbead suspension onto the Formvar carbon-coated 
400 mesh copper grids (Electron Microscopy Sciences) and dried in air.  
3.2.6 Magnetic Properties 
The PVA-IONP microbeads (75.24 mg/mL) were suspended were placed in a 
microcentrifuge tube (ThermoFisher Scientific) filled with 1 mL PBS solution. A 
permanent magnet was then introduced close to the tube for a selected time interval. The 
movement of microbeads towards the magnet and their settling upon magnet removal was 
recorded using a camera.   
The hysteresis loop of dried microparticles was tested using a vibrating sample 




3.2.7 MR Contrast Effect 
For the MR images, PVA-IONP microbeads were placed in 1.5mL centrifuge tubes at 
varying masses. Neat 5wt% PVA hydrogel was homogenized and used as the control. All 
tubes were filled with agar phantom material described elsewhere [18] and then placed in 
a large plastic container also containing agar phantom material.  
MRI contrast enhancement was examined using a clinical 3T MRI scanner (Siemens 
Healthcare, Erlangen, Germany). Scans were performed at 350 ms repetition, 3.5-15 ms 
echo-time, 3mm (axial) and 4mm (coronal) section thickness, 4.8 mm (axial) and 3.6 mm 
(coronal) intersection spacing, 88x192 matrix size and 65x141mm field of view to 
acquire T2-weighted images. 
3.2.8 In vitro Degradation Measurements 
Degradation of the PVA-IONP microbeads was studied by placing 1.5mL hydrated beads 
(76 mg/mL) into a dialysis kit (2mL Mini Dialysis Kit, 1kDa, GE Healthcare) and 
performing dialysis against 3 mL DMEM (pH=7.4, used as received; pH=5.5, adjusting 
pH using HCl) at 37 C. At predetermined time points, the solution outside the dialysis 
kit was collected, and the amount of released iron content was analyzed using atomic 
absorption spectroscopy (AAS, Varian Spectra AA-55) at the wavelength of 248.3 nm. 
Once the degradation medium was removed, the dialysis kit was placed in an equal 
volume of fresh release medium. Each experiment was carried out in triplicate. To 
determine the percentile of released iron, the total iron content of microbeads was 
extracted by dissolving the microbeads using diluted HCl. The solubilized iron content 
was subsequently quantified using AAS. 
3.2.9 Loading and in vitro Release of DOX 
Loading of DOX was achieved by soaking PVA-IONP hydrated microbeads (0.25 mL) 
into a doxorubicin solution (equivalent DOX concentration 0.25 mg/mL, 1mL) at room 
temperature overnight. The resulted products were collected by a permanent magnet and 




The amount of doxorubicin in the supernatant was quantified using a UV 
spectrophotometer (Cary 60 UV-Vis, Agilent Technologies Inc.) at 485 nm.  The loading 




) = (W0 − Wt)/V b 
(2) 
 
Loading efficiency was determined by Equation 3 as follows: 
Loading efficiency (%) =
(𝑊0−𝑊𝑡)
𝑊0
× 100% (3) 
 
where W0 is the initial weight of DOX in solution, Wt is the weight of DOX in the 
supernatant, and Vb is the volume of hydrated PVA-IONP beads. 
To study the in vitro release of DOX, drug-loaded microbeads were resuspended into 15 
mL release buffer (PBS, pH=7.4 and phosphate buffer, pH 5.5) and then placed in a 
shaking water bath (New Brunswick Scientific, USA) maintained at 37 C with gentle 
shaking (rpm=110). At predetermined release intervals, a supernatant of 1 mL was 
withdrawn from each sample and analyzed as described before. Subsequently, 1 mL of 
fresh release media was added to the microbeads to keep the total volume constant.  
The cumulative DOX release was calculated by Equation 4: 





where Mt is the amount of DOX released at time t, M∞ is the amount of DOX loaded on 
the microbeads. 
3.2.10 Statistical Analysis 
For DOX loading study, a sample size of six was used. For DOX release and microbeads 
degradation study, a sample size of three was used at each experimental condition. 
Statistical analysis was performed using Microsoft Excel and OriginLab 2019b 






3.3.1 Droplets Generation and Size Analysis 
The dispersed phase was broken into droplets at the narrow orifice by continuous phase 
(Figure 3.1). The droplets solidified in the NaOH solution and retained a teardrop shape. 
All the microbeads exhibited brownish-yellow color (Figure 3.2 A). The microbeads 
followed a relatively narrow size distribution with an equivalent spherical diameter of 95 
± 22 μm (Figure 3.2 B). 
 
Figure 3.1 Fabrication of PVA-IONP microbeads using a flow-focusing microfluidic 
channel. The red arrow indicates flow of the dispersed phase, the blue arrow 
indicates flow of the continuous phase, and the black arrow indicates the generated 






Figure 3.2 (A) Optical microcopy image of fabricated PVA-IONP microbeads and 
(B) histogram of microbead equivalent spherical diameter fit to a Gaussian 
distribution. Microbeads were in a teardrop shape with a relatively narrow size 
distribution. 
3.3.2 Morphological, Elemental and Structural Features of 
Microparticles 
The morphology of the beads was examined using SEM and results are shown in Figure 
3.3 A-C. EDX analysis of the microbeads confirmed the presence of iron inside of the 





Figure 3.3 (A)-(C) SEM images of PVA-IONP microbeads. (A) displays a whole 
bead, (B) and (C) show surface morphology. (D) Whole microbead with a square 
specifying the location of EDX sampling. (E) EDX spectrum indicating the presence 
of iron in the PVA-IONP microbeads. 
Inspection of beads by TEM revealed the presence of iron in the form of IONPs with a 
uniform spherical shape (Figure 3.4 A) with minimum aggregation. The size distribution 
histogram showed a narrow size distribution of IONPs with a mean diameter of 11 nm 






Figure 3.4 (A) TEM micrograph of PVA-IONP microbeads. The black arrow 
indicates an individual iron oxide nanoparticle, the red arrow indicates a polymer-
rich region, and the blue arrow indicates a polymer-poor region. (B) Histogram of 
diameter of dispersed IONPs fit to a Gaussian distribution. IONPs were in spherical 
shape with minimum aggregation. IONPs were observed to distribute at the 
interface of polymer-rich and polymer-poor regions. 
3.3.3 Magnetic Properties 
The magnetic properties of microbeads were first examined visually in stagnant PBS. 
Upon introducing the magnet, the beads moved towards it. Once the magnet was 
removed, all beads slowly settled down due to gravity (Figure 3.5 A).  
The magnetization study of PVA-IONP microbeads was performed at 25 C. The 
symmetrical sigmoidal shape of the magnetization curve in the absence of a hysteresis 
loop indicated a superparamagnetic behavior (Figure 3.5 B). A saturation magnetization 





Figure 3.5 (A) Magnetic responsiveness of PVA-IONP microbeads upon introducing 
of a permanent magnet close to the sample. The microparticles were attracted by 
the magnet and would completely settle down due to gravity after the magnet was 
removed. (B) Magnetic susceptibility of the microbeads. The absence of a hysteresis 
loop indicates a superparamagnetic behavior of the PVA-IONP microbeads. The 
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3.3.4 MR Contrast Effect 
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ghted images. An enhanced contrast against background was observed relative to a 
control sample of neat PVA, thus confirming the effectiveness of iron oxide as a contrast 
agent. In addition, a more prominent darkening effect was observed with a greater 
amount of microbeads, indicating the contrast effect is correlated to the density of 
microbeads hence the IONPs. 
 
Figure 3.6 T2-weighted MRI images of microbeads at different quantities (3T, 
repetition time 350 ms, echo-time 3.5-15 ms). The white arrow indicates the 
presence of PVA-IONP microbeads and their contrast effect on T2-weighted images. 
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3.3.5 In vitro Degradation 
Degradation of PVA-IONP microbeads was studied in DMEM at pH 7.4 and 5.5 for more 
than 50 days. The degradation is measured quantitatively as iron release and qualitatively 
as PVA matrix disintegration.  
As depicted in Figure 3.7 A, iron release from microbeads appeared to be a two-stage 
release with non-significant dependence on pH. Iron release rate remained slow at the 
first stage (day 0-day 17), with less than 2.5% of total iron was released from microbeads 
under both conditions. The release rate was faster at the second stage (day 18-day 52) 
without reaching a plateau by the end of the measurements. After day 17, more than 20% 
of total iron was released in 5 weeks, resulting in a ~26% cumulative release for 
microbeads under acidic pH, while this number reached ~23% for samples under 
physiological pH.  
Due to the small value of the sample weight, we were not able to measure the weight loss 
of the sample directly. However, the development of transparent beads (Figure 3.7 B and 
C) revealed the release of IONPs, which can be taken as part of mass loss hence 
degradation of PVA-IONP beads. In addition, SEM images of the beads at day 30 (Figure 
3.7 D) showed changes in morphology, which confirmed the dissolution and 






Figure 3.7 Degradation of the PVA-IONP beads. (A) Cumulative iron released from 
the microbeads. (B) and (C) are optical images of beads at day 0 and day 30, 
respectively. (D) SEM micrograph of beads at day 30. Degradation study was 
performed in DMEM at pH 5.5, 7,4 and 37 ℃. More than 20% of total iron was 
released in 5 weeks for both conditions. The removal of IONPs can be further 
visualized through the color change of the microparticles. The PVA-IONP 
microparticles lost the original teardrop shape during the incubation. The release of 





3.3.6 DOX Loading and in vitro Release 
Due to the abundant presence of hydroxyl groups in the PVA matrix, the microbeads are 
anticipated to be capable of loading with hydrophilic drugs such as DOX, through van 
der Waals interaction and hydrogen bonding [19]. The PVA-IONP microbeads allowed a 
DOX loading capacity of 0.49 ± 0.02 mg/mL with a loading efficiency of 48.8 ± 2.5%.  
As shown in Figure 3.8, a sustained and pH-dependent DOX release profile was observed 
during the course of 7 days. For microparticles at pH 7.4, ~20% of DOX was released 
within 1 hour and a maximum release of 32% was reached within 7 days. Acidic 
environment significantly accelerated the DOX release such that ~33% of the drug was 
released within the first hour and ~ 53% of Dox was released within a week. 
 
Figure 3.8 Profiles of cumulative percent doxorubicin release with time from PVA-
IONP beads in PBS at pH 7.4, 5.5 and 37 ℃. The DOX loading was 0.49 ± 0.02 
mg/mL with a loading efficiency of 48.8 ± 2.5%. Microparticles can provide a 
controlled release for DOX for 7 days. Acidic environment contributes to a faster 





3.4.1 Fabrication of PVA-IONP Microparticles 
Microfluidic fabrication was effective in producing PVA-IONP microparticles, resulting 
in an equivalent spherical diameter of 95 ± 22 μm. In a flow-focusing geometry, at the 
intersection, the central fluid (dispersed phase, PVA with IONP precursors) was 
hydrodynamically flow focused by the fluid (oil phase, 1 wt.% Span80 in undecane) in 
the two side channels. A pressure gradient along the long axis of the device forced two 
liquids through the narrow orifice. Due to the wettability of the two phases to the 
hydrophobic PMMA channel [20], only the oil phase can adhere to the channel wall, 
hence the flow of the dispersed phase was pinched off by the oil phase to create droplets 
[21,22], forming downstream water-in-oil droplets. These iron salts containing droplets 
fell into the NaOH solution, which triggered the reaction shown in Equation 5, leading to 
the formation of Fe3O4 nanoparticles inside the solidified PVA hydrogel microbeads. 
These beads were further processed using the LTTC process to impart enhanced stability.  
2FeCl3 + FeCl2 + 8NaOH ⟶ Fe3O4 + 8NaCl + 4H2O (5) 
Interestingly, the shape of the PVA-IONP microparticles was non-spherical. The initial 
generation of non-spherical droplets was suspected to result from the viscous dispersed 
phase. According to Nie et al. [23], for high viscosity liquids, the surface tension-driven 
collapse of the neck at the last stage is slow, which would take longer for droplets to 
break up. In addition, the planar design of the microchannel only allows quasi-2-D 
contact of fluids. While fully shearing off the viscous disperse phase, the flow of disperse 
phase was elongated into a teardrop shape due to the combined outcome of shear force 
and viscoelastic effect [23–26].  Although the droplets would attempt to recover a 
spherical shape in order to minimize the interfacial free energy after leaving the 
microchannel [27], as the droplet fell into the NaOH solution, the combined forces 
applied to the surface of the droplet (e.g., gravity, buoyancy, interfacial tension and drag 
force), as well as the rigidity change induced by the co-precipitation, would preserve the 




Apart from the shape, the size and size distribution of the microbeads must also be 
considered. The equivalent spherical diameter of the beads was measured as 95 ± 22 m, 
which size falls in the range of large arteries and capillaries [28,29]. For TACE therapy, 
particles with a diameter smaller than 500 m would be desired [30], as they can be 
easily administered by a catheter and reach the reach in close proximity to a tumor and 
adequately occlude the vessels [12,31,32].  
Despite the teardrop geometry, the PVA-IONP microparticles were fairly uniform in 
shape with a reproducible size, making them suitable for serving as embolic agents. Some 
irregularly shaped materials, such as ContourTM (Boston Scientific/Target Therapeutics, 
USA) and Ivalon PVA blocks, have been used for artery embolization [33]. Although it 
has been suggested that particles with uniform size and shape may reach more distal 
locations and has a low probability to form proximal aggregates than irregular materials 
or material with irregular shape [34–36]. Modifications to address the irregular shape can 
be made by diluting dispersed phase to reduce the viscosity of the fluid, or by adopting a 
3-D coaxial design for the flow-focusing channel [37]. 
3.4.2 Morphological, Elemental and Structural Features of 
Microparticles 
EDX confirmed the successful incorporation of IONPs into the PVA matrix. The size, 
shape and dispersity of IONPs were further examined by TEM. IONPs formed were very 
uniform in size with little or no aggregation (Figure 3.4 A). They were also found to be 
distributed at the water-rich regions, adjacent to the interface of polymer-rich and water-
rich regions. This type of distribution could be explained by the partition behavior of 
IONP precursors between the two phases, as iron salts have higher solubility and 
diffusivity in the aqueous phase (i.e., polymer-poor region) [15]. 
Size uniformity and good dispersity of IONPs are crucial factors as they govern the 
magnetic behavior and the performance as a T2 contrast agent [39]. From the TEM 
micrographs, the size of IONPs in the PVA matrix was 11± 2 nm with minimum 




behave superparamagnetically [40], which was confirmed by the VSM result (Figure 3.5 
B).  
3.4.3 Magnetic Properties  
The magnetic property of PVA-IONP beads was confirmed by their movements towards 
a permanent magnet, which indicated the potential application in magnetically-guided 
drug delivery (Figure 3.5 A). Kumar et al. [28] were able to steer a group of 
microparticles (D=200 m) with a cylindrical magnet (B=2T) in a simulated body fluid. 
The beads can be propelled in parallel, antiparallel and angular directions in a linear 
assembly. It is to be expected that these magnetic particles will be exposed to a more 
complicated in vivo hydrodynamic environment where a combined effect of gravity, drag 
force, magnetic force and intermolecular repulsive force will govern the locomotion of 
particles [28,41]. However, with a deeper understanding of fluid dynamics and mechanics 
and proper MRI gradient coil and designed algorithm, the particle trajectory can be 
designed and controlled. For example, Chanu et al. [42] has successfully applied a 
closed-loop control scheme and achieved automatic guidance of a single magnetic bead 
(D=1.5 mm) in the carotid artery of a 25 kg living swine.  
The superparamagnetic property of the PVA-IONP microparticles was evident from the 
absence of coercivity and remanence magnetization, suggesting the in situ co-
precipitation was effective in preparing superparamagnetic hydrogels. During the 
reaction, the PVA network can potentially prevent agglomeration of IONP and makes it 
low nanometer in size and well-dispersed [43]. In addition, PVA can serve as a stabilizer 
to prevent Fe3O4 nanoparticles from exposure to O2, therefore prevent them from 
oxidization [44].  
A decrease in the Ms value (9.36 emu/g) compared to bulk magnetite (~90 emu/g) was 
apparent [45]. This can be contributed by the reduced particle size of superparamagnetic 
IONPs [46,47] and the dilution effect from adsorbed water and hydroxyl (-OH) content 
[45]. Also, the PVA matrix could act as a dead layer to restrict the magnetic coupling 




Taken all together, the development of superparamagnetic microparticles is useful in 
magnetic field-related applications such as magnetically-guided drug delivery. These 
particles can follow the pre-designed route to reach the targeted site through a fine spatial 
control [50]. This superparamagnetic property can potentially be helpful in MRI, as it can 
filter background effects of biological paramagnetic materials (e.g., deoxymyoglobin and 
deoxyhemoglobin) to obtain images with better contrast [51]. 
3.4.4 MR Contrast Effect 
With an increased IONPs weight in the sample, a darkening effect in T2 image was 
observed as expected. It was reported by Wabler et al. [52] that T2-weighted contrast 
positively correlated with a total iron concentration in the samples, this can be understood 
that the transverse proton relaxation rate (R2) increased with an increased IONP 
concentration due to the signal dephasing effects of magnetic nanoparticles [53–55].  
The detectability of beads will be extremely helpful in clinical practice to address the lack 
of feedback during DEB-TACE procedure [56]. The distribution of beads can provide a 
real-time location to guide the intervention. More importantly, since the drugs and the 
IONPs are co-localized in the microbeads, the location of beads can serve as a surrogate 
to report on local drug concentrations. 
3.4.5 In vitro Degradation 
It was found that negligible iron content (less than 2.5%) was released in the first 17 
days, indicating a strong binding between the IONPs and PVA (Figure 3.7 A). The 
relatively faster release in the following weeks could be a result of fast dissolution and 
diffusion of IONP at the outmost layer of the gel beads [19]. However, this iron release 
profile could still be helpful in TACE therapy, as imaging is usually required after 2-7 
days and 3-6 weeks after the first treatment to assess the tumor response [57]. This IONP 
release rate can potentially provide sufficient amount of IONPs for each imaging session 
[4,57,58].  
It is worth noting that the pH effect on IONP release was not significant, which may be 




IONP release from swellable hydrophilic PVA matrix could be contributed by a series of 
physical and chemical process, involving liquid penetration into the polymer network, the 
hydration and swelling of PVA matrix, dissolution reaction, solubilized iron content 
diffusion throughout swollen matrix and, possibly with, the degradation of polymer 
matrix [59]. Among all the processes, the diffusion process can be rate-controlling. 
Therefore, all IONPs accessed by HCl can be reacted and converted to soluble iron salts 
within the sampling interval. However, dissolved iron content was retained in the PVA 
hydrogel and diffused into the medium at a pace determined by the diffusivity, hence the 
degradation of the polymer matrix [60].  
In our previous study on the PVA-IONP bulk material, we have demonstrated the 
removal of iron mechanically weakens the hydrogel and contributes to the total mass loss 
of the sample [16]. The authors hypothesized that the stability of the hydrogel was 
provided by the IONP crosslinking and the physical crosslinking by the LTTC process. 
The degradation of the material can be regarded as the total mass loss of the hydrogel 
contributed by the loss or release of iron and the material dissolution.  
In this study, the release of IONPs was quantified by the AAS. The SEM observation 
(Figure 3.7 D) provided qualitative evidence. The shape loss and polymer matrix 
disintegration were clearly observed on the microparticles at day 30, indicating the 
degradation of PVA-IONP microbeads.  
Degradable materials could be advantageous in tumor embolization as they provide 
transient embolic effects, which can potentially prevent the occurrence of the post-
embolization syndrome, tissue inflammation and fibrosis, and risks from non-target 
embolization [13,14]. Particularly for patients with HCC, it is reported that over 90% of 
patients need repeated treatments. As such, degradable microparticles would ideally 
permit multiple TACE procedures hence better treatment outcomes [33].   
3.4.6 DOX Loading and in vitro Release 
The PVA-IONP microbeads supported sustained DOX release at pH 7.4 and pH 5.5, and 




contents reached 51.0 ± 2.2% by 7 days, almost 1.6 times of the release at healthy 
physiological pH. This greater release may be resulted from the protonation of the 
primary amine groups (-NH2) of DOX under an acidic environment, depriving the sites 
available for hydrogen bonding with PVA. 
The microparticles developed incomplete DOX release at both pH conditions, indicating 
the solute release may be controlled by hydrogen bonding and degradation of 
microparticles. Taken the degradation measurements together, it is likely that the slow 
degradation of PVA contributes to the incomplete release of DOX. Nevertheless, the 
DOX release was in a controlled manner for one week, which could potentially result in a 
more significant impact on tumor kill. 
3.5 Conclusion 
This work successfully synthesized novel composite hydrogel microbeads using 
microfluidic fabrication and in situ co-precipitation for IONP synthesis within the PVA 
matrix. The resulting drug delivery systems were in a teardrop shape with a relatively 
narrow size distribution. The microparticles exhibited superparamagnetic properties and 
were effective in producing a contrast-enhancing effect on MR images. Such properties 
also suggest the feasibility of magnetically-guided drug delivery and in vivo imaging 
during/post the intervention. Moreover, PVA-IONP microparticles were degradable, 
allowing repeatable TACE to be applied. Degradation occurred in the form of iron release 
and matrix disintegration. Moreover, these microparticles acted as a suitable carrier for 
DOX and rendered a controlled release for a course of one week. All these outstanding 
characteristics make PVA-IONP microparticles an improved DEB system in TACE 
therapy. 
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Chapter 4  
4 Development of a Multifunctional Bioactive 
Protein/Peptide Delivery System for Dry Eye Disease2 
4.1 Introduction 
Dry eye disease (DED) is a multifactorial disease characterized by inflammation that 
damages the ocular surface and tear producing glands [3,4]. Tear film instability or 
osmolarity changes, among others, stress underlying corneal epithelial cells, inducing 
further release of pro-inflammatory cytokines, including interferon-γ (IFNγ) and tumor 
necrosis factor (TNF) [3,5,6]. All severities of DED substantially reduce health-related 
quality of life [7]. Worldwide prevalence is estimated at 5.5–33.7% with Canada at 25%, 
but underestimates may result from patients’ failure to recognize or report symptoms, 
indicating a large public health issue [4,8]. 
Eye drops are widely used to deliver artificial tears and anti-inflammatory agents to the 
ocular surface of DED patients [5]. This method fails to sustain drug delivery, with less 
than 5% of the topically applied drug dose reaching target corneal tissue. Rapid drug 
elimination can be attributed to blinking, the tear film barrier, reflex tearing, and drainage 
through tear ducts [9]. Losing over 95% of the formulation’s dose during drug delivery 
not only impairs cost-effectiveness but also requires diligent patient compliance with 
frequent dosing throughout the day to maintain adequate efficacy within target tissues. 
Such high patient compliance is not consistently attainable, likely decreasing therapeutic 
effectiveness.  
Current pharmaceutical agents commonly used to treat DED are also unfavorable as long-
term solutions. Artificial tears provide only temporary lubrication without addressing the 
underlying pathology of DED, with most formulations lacking bioactive tear components 
[10,11]. Long-term use of corticosteroid eye drops may increase the risk of developing 
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glaucoma, cataracts, and bacterial infections [3,5,10]. Prolonged use of cyclosporine can 
lead to complications such as lid maceration and corneal epitheliopathy [12]. Indeed, few 
physicians in White et al.’s study were satisfied with the ability of cyclosporine and 
lifitegrast to manage DED symptoms and improve quality of life [13]. 
The development of protein and peptide-based therapeutics is rapidly increasing for the 
treatment of a wide variety of clinical indications [14]. Inorganic nanoparticles such as 
gold nanoparticles (AuNPs), iron oxide NPs (IONPs), and silica NPs (SiNPs) have also 
been extensively investigated. They are highly biocompatible, with some formulations 
proceeding to the clinical trial stage [15]. Among these, SiNPs are especially promising 
as carriers for ophthalmic therapeutics to overcome the bioavailability limitation of 
traditional eye drops. Generally Recognized as Safe (GRAS) by the FDA, SiNPs are 
generally not cytotoxic to human corneal epithelial cells (HCECs), with larger diameters 
having a lower risk of cytotoxicity [16–18]. Lysozyme is widely used in the study of 
silica-protein interactions due to its conformational stability and similar properties to 
numerous bioactive proteins [19,20]. In addition to its prototypical features, lysozyme 
possesses antimicrobial, anti-inflammatory properties and is also a major component of 
the tear film [21–23].  
Lacritin has many desirable properties conducive to its development as a therapeutic 
agent for DED. It is a human tear glycoprotein secreted by the lacrimal glands and 
downregulated in DED tears [24,25]. Topical application enhances basal tearing in 
rabbits [10,26]. It is mitogenic and cytoprotective on HCECs in vitro [27,28]. Its C-
terminus is bactericidal and rescues HCECs stressed by inflammatory mediators IFNγ 
and TNF by stimulating an autophagy pathway to clear damaged organelles and proteins 
[29–31]. Because its C-terminus has a heparanase-dependent binding mechanism to 
syndecan-1, lacritin binding targets areas of the eye highly associated with DED [32,33]. 
Since lacritin’s C-terminus mediates receptor activation and thus prosecretory, 
bactericidal, and cytoprotective activity, the N-94 fragment should be equipotent to the 
complete protein. We investigated a synthetic 25-amino acid lacritin peptide (N-94) 




94 is smaller and has a more suitable isoelectric point than lacritin, maximizing its 
loading potential onto SiNPs. Preliminary studies indicate that N-94 has a predicted 
isoelectric point (IEP) of 10.5 while lacritin has an IEP of 5 [34]. At physiological pH, N-
94 would be positively charged to aid in its adsorption to the negatively charged SiNP 
surface [35]. 
The use of SiNPs as a controlled release delivery system for the N-94 offers several 
advantages for the treatment of DED. Since the N-94 fragment decomposes readily on the 
inflammatory and oxidative ocular surface, the N-94-SiNPs would allow for sustained 
availability of N-94 over time [2]. Furthermore, the loading, release time profile, and 
dosage can be tuned based on clinical needs.  
While an existing study found that lacritin reduces HCEC death induced by pro-
inflammatory cytokines, it was unconfirmed whether N-94 had similar cytoprotective 
effects [29]. The biocompatibility of N-94 and N-94-conjugated SiNPs (N-94-SiNPs) 
with HCECs was also yet to be elucidated.  
In is study, we synthesized the SiNPs using the Stöber method. Their drug loading and 
controlled release properties were characterized using lysozyme as a model protein. 
Dissolution of the SiNPs was also demonstrated. N-94 was subsequently conjugated to 
SiNPs, its release profile, presence of toxicity to HCECs, and cytoprotective activity were 
also studied to assess the feasibility of the conjugated system for treating DED. 
4.2 Materials and Methods 
4.2.1 Materials 
All chemicals were used as received without further purification. Tetraethylorthosilicate 
(TEOS, 99+%) and lysozyme from chicken egg white (minimum 23,500 units/mg 
protein) were purchased from Alfa Aesar, ammonium hydroxide (28%-30% NH3 in H2O) 
was obtained from Caledon. Phosphate buffered saline tablets and dimethylsulfoxide 
(DMSO) were purchased from Sigma-Aldrich. Ethanol (95%) was obtained from 
Commercial Alcohols. Inflammatory cytokines IFNγ and TNF were acquired from 




custom-made with fluorescein isothiocyanate (FITC) and a seven-atom aminohexanoyl 
spacer covalently conjugated to the peptide’s N-terminus to allow for quantification via 
fluorescence spectrophotometry. Distilled water was used for all experiments.  
4.2.2 Preparation and Characterization of Protein/Peptide-SiNPs 
Conjugates  
SiNPs were synthesized by the Stöber method [217]. In a typical synthesis, solution 
containing 5 mL ethanol and 10 mL ammonia was prepared. After equilibration at room 
temperature (23  1C), 100 L TEOS was added dropwise and the reaction was 
maintained at the same temperature for 1 hour under constant stirring. The resulting white 
precipitate was separated by centrifugation (Sorvall RC5C, Sorvall Instruments, USA), 
washed with water and ethanol, and dried at 60 C under vacuum overnight for future 
use.  
To prepare lysozyme loaded SiNPs for characterization, conjugates were prepared from a 
relatively concentrated lysozyme solution (10 mg/mL, 1 mL) and 15 mg SiNPs. To load 
N-94 onto the SiNPs, a 20:1 ratio (w/w) of SiNP:N-94 each suspended in equal volumes 
of PBS were combined in Eppendorf tubes. Adsorption was allowed for 48 hours at room 
temperature for both formulations. Pellets were separated and rinsed with PBS to remove 
loosely attached lysozyme molecules. FTIR (Bruker Vector, USA) and scanning electron 
microscopy (SEM, LEO1540XB FIB/SEM, ZEISS, USA) were performed on both air-
dried bare SiNPs and protein/peptide-SiNPs conjugates. 
4.2.3 Protein Adsorption Kinetics and Isotherms 
For the adsorption kinetics studies, lysozyme-SiNP conjugates were prepared by mixing 
100 mg of SiNPs in a beaker containing 12 mL of a 0.5 mg/mL lysozyme in 1x PBS 
solution (pH 7.4). Adsorption was performed at room temperature in an orbital shaker 
(New Brunswick Scientific) at 75 rpm. All experiments were performed in triplicate.  
At pre-determined time points, 0.5 mL supernatant was retrieved. Lysozyme 
concentration in the supernatant was determined by a Cary UV-vis spectrophotometer 




The amount of lysozyme adsorbed onto SiNPs at time t, Qt was determined by the 






where C0 and Ct are the concentration of lysozyme in the stock solution and in the 
suspension at time t (mg/L), respectively. V is the total volume of the solution (in L), and 
m is the weight of SiNPs (g).  
Isotherm studies were performed with a constant dosage of SiNPs (15 mg/mL in the final 
mixture) and varying concentrations of lysozyme (C0)  in the range of 133 mg/L to 3000 
mg/L. The mixture was shaken at 160 rpm for 48 h at ambient temperature. Finally, 
samples were centrifuged for 5 minutes at 8,000 rpm to retrieve supernatant, which was 
subject to UV-vis for lysozyme quantification. 
4.2.4 Protein/Peptide Release in the Absence of Cells 
The release of bioactive protein/peptide from SiNPs were characterized using lysozyme 
and N-94 as the prototypical molecules. Lysozyme-SiNP and N-94-SiNP conjugates were 
prepared separately by mixing SiNPs and corresponding adsorbates at a 20:1 ratio (w/w). 
Adsorption was maintained at room temperature in an orbital shaker at 75 rpm for 48 
hours. The resulting conjugates were rinsed with PBS and transferred to microcentrifuge 
tubes (Sigma-Aldrich) containing 1 mL PBS in each. Release was then carried out at 
37C in the orbital shaker at 75 rpm. At pre-determined time points, supernatant was 
replaced with fresh PBS to maintain the total volume constant.  
The amount of adsorbed/released adsorbates was determined by UV-vis in the case of 
lysozyme, while for N-94 quantification, a SpectraMax M3 Multi-Mode Microplate 
Reader (Molecular Devices, LLC, CA) was used. Samples were excited at 496 nm and 
emission intensity at 520 nm was acquired. In addition, matrix assisted laser desorption 
ionization-time of flight mass spectrometry (MALDI-TOF MS) was used to verify the 
integrity of pre-conjugated and released N-94 samples obtained at 8 hours, suspended in 
ultrapure water. Samples were mixed at a 1:1 ratio (v/v) with an α-cyano-4-




trifluoroacetic acid) and spotted on the MALDI plate in duplicates. MS data were 
obtained using an AB Sciex 5800 TOF/TOF System (Framingham, MA).  Data 
acquisition and processing were done using an AB Sciex TOF/TOF Series Explorer and 
Data Explorer. 
4.2.5 Dissolution of SiNPs in the Absence of Cells  
In vitro degradation was studied in PBS at 37C with SiNPs alone. Typically, 10 mg of 
SiNPs were added into 5 mL of PBS and samples were incubated in a shaker at 75 rpm. 
PBS was replaced every 5 days to prevent solution saturation. At pre-determined time 
points, solid SiNPs were retrieved, washed, and resuspended in water. Transmission 
electron microscopy (TEM, PhillipsCM10) graphs were taken to examine the structural 
changes of SiNPs during the degradation. TEM samples were prepared by dropping this 
suspension onto a Formavar carbon-coated copper grid. 
4.2.6 Cell Culture 
Primary human corneal epithelial cells (HCECs) obtained from three different donors 
were purchased from American Type Culture Collection (ATCC, Manassas, VA). 
HCECs at the second passage at the time of purchase were cultured in colorless, 
keratinocyte-serum free Corneal Epithelial Cell Basal Medium with Corneal Epithelial 
Cell Growth Kit supplements (ATCC). For all experiments, cultured cells were seeded in 
24-well plates directly into the wells or into trans-well inserts at a density of 2×105 
cells/cm2 and treated when 80% confluent. 
4.2.7 Determination of Optimal Pro-inflammatory Cytokines IFNγ & 
TNF Concentration 
Using Wang et al.’s study as a guideline, a fixed IFNγ concentration of 100 U/mL was 
combined with varying concentrations of TNF to insult HCECs for 16 or 20 hours [29]. 
The combination that reduced cellular metabolic activity from 100% to about 65–75% 
was used to stress HCECs.  The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 




4.2.8 Effects of N-94 on HCECs  
Effect of N-94 on HCECs was evaluated in terms of cytotoxicity and cryoprotection. To 
detect potential cytotoxicity, HCECs were treated with 1–10 000 nM of N-94 for 1–24 
hours. Cells cultured in medium without the addition of N-94 were used as negative 
controls (“vehicle control”).  
At designated times, cell viability was determined by the measurement of cellular 
metabolic activity using the MTT assay. Briefly, cells were incubated in 24-well plates in 
serum-free conditions with 450 μg/mL MTT solution (Sigma-Aldrich) for 3 hours at 
37oC. After aspirating excess MTT, dimethylsulfoxide (DMSO, Sigma-Aldrich) was 
added and plates were shaken. Samples were transferred to 96-well plates in triplicate, 
with a few wells reserved for DMSO only. Absorbances were read at 575 nm by the 
iMark Microplate Reader (Bio-Rad Laboratories). The DMSO absorbance was subtracted 
from all other absorbances. The cellular metabolic activity of experimental groups was 
normalized by the vehicle control group (100%) in all cellular studies and expressed as 
percentages. 
To investigate the cytoprotective effects of N-94 on HCECs, HCECs were 
simultaneously treated with 1–10 000 nM of N-94 and pro-inflammatory cytokines of the 
optimal concentration combination for 16 and 20 hours. The positive control consisted of 
HCECs stressed by cytokines in the absence of N-94 (“insult only”). The negative control 
was untreated, healthy HCECs incubated in cell medium only (“vehicle control”). The 
MTT assay was performed to determine cellular metabolic activity. 
4.2.9 Effect of N-94-SiNPs on HCECs  
Cytotoxicity and cytoprotective effect of the complete delivery system (i.e., N-94-SiNPs) 
on HCECs were assessed. N-94-SiNPs were prepared as per section 2.4 in concentrations 
of 5.6–5600 nM. Based on preceding experiments, it was assumed that 90% is adsorbed 
and 40% is maximally released, along with a 50% dilution during treatment, yielding 
final treatment concentrations of 1–1000 nM. Release of N-94 was conducted in a water 





N-94-SiNPs treatments were then performed in a non-contact manner. HCECs were 
cultured in trans-well inserts (0.4 µm pores, Falcon, Canada) placed into compatible 24-
well plates. Each well contained treatment basolateral to the cells and cell culture 
medium apical to the cells. The controls were cell culture medium with PBS only 
(“vehicle control”) and SiNP treatment only. 
At designated times, cells in the culture inserts were subjected to the MTT assay, while 
apical and basolateral supernatants were combined from each well and subjected to the 
lactate dehydrogenase (LDH) assay. LDH standards were prepared and loaded with 
supernatant samples in triplicate into 96-well plates. Reaction solution was prepared 
using an LDH assay kit (Sigma-Aldrich) then added to each sample and standard. Plates 
were incubated for 10 minutes at 37 oC and absorbances were read using a dual filter at 
490 nm and 655 nm by the iMark Microplate Reader. LDH concentrations were 
calculated using the standard curve. LDH release of experimental groups was normalized 
by the vehicle control group (100%) and expressed as percentages. 
To evaluate the cytoprotective property of released N-94, N-94 loading and release were 
performed as per section 4.2.4. After release was complete, tubes were centrifuged and 
supernatant samples containing the released N-94 were extracted as the treatment. 
HCECs were then co-treated with 100 U/mL of IFNγ and 12.5 ng/mL of TNF and 1–
1000 nM of released N-94 in PBS for 16 and 20 hours. The controls were cell culture 
medium with PBS only (“vehicle control”) and cytokine insult only (“insult only”). 
Afterwards, apical supernatants were collected and analyzed using LDH and MTT 
assays. 
4.2.10 Statistics 
A one-way analysis of variance (ANOVA) was performed on the diameter of the silica 
nanoparticles using OriginLab 2019b (OriginLab Corporation, MA). For protein/peptide 
release and biological studies, three biological replicates (i.e., cell lines from distinct 
donors) and three technical replicates of each cell line were performed for each cellular 




ANOVAs and post-hoc tests. Values of P < 0.05 were considered statistically significant. 
All results are reported as the mean ± standard deviation. 
4.3 Results 
4.3.1 Preparation and Characterization of Protein/Peptide-SiNPs 
Conjugates  
SiNPs were synthesized using a Stöber procedure [36]. The product nanoparticles were 
characterized in terms of their morphology, size, and size distribution. The SEM 
micrograph in Figure 4.1 A shows that the SiNPs are spherical and non-porous with a 
fairly uniform size and minimum aggregation. Uniformity of the SiNPs’ size was 
confirmed by the narrow size distribution shown in the insert. The average diameter was 
determined to be 251  19 nm. In the N-94 study, a new batch of SiNPs with good size 
uniformity (374 ± 15 nm) was prepared and used (Figure 4.1 B). Particle size can be 
tuned by varying a combination of reaction time, temperature and reactants ratio [37].  
 
Figure 4.1 SEM of SiNPs used in (A) lysozyme and (B) N-94 study. Insert is the 
particle size distribution.  
Lysozyme and N-94 molecules were conjugated to the SiNPs by batch adsorption. The 
adsorption of such molecules onto the surface of the SiNPs is visible (Figure 4.2 A). 
Lysozyme loading was further confirmed by FTIR. The absorption band at ~1650 cm-1 in 
the FTIR spectrum corresponds closely to the amide I peak for proteins [38]. the major 




94 was also successfully conjugated onto the SiNPs. The amount of N-94 conjugated was 
too small for FTIR analysis. However, characterization of the N-94 recovered in 
controlled release experiments shown in Figure 4.4 D serves as indirect evidence of 
loading success. 
 
Figure 4.2 (A) SEM of lysozyme-loaded SiNPs. The red arrow indicates the presence 
of lysozyme. Insert: FTIR spectrum of SiNPs, lysozyme powder and lysozyme-
SiNPs. The red arrow indicates the characteristic bands of proteins, and the black 
arrow indicates the characteristic bands of silica. (B) SEM of N-94-loaded SiNPs. 
The SEM micrographs and FTIR spectrum confirm the loading of lysozyme and N-
94 onto the SiNPs surface. 
4.3.2 Adsorption Kinetics and Isotherms  
To better understand the adsorption mechanism, kinetic data was analyzed using pseudo-
first-order and pseudo-second-order models, according to ref. [39] 
Pseudo-first-order kinetic: 





















where Qe (mg/g) represents the amount of lysozyme being adsorbed at equilibrium. k1 
(h−1) and k2 (g·mg
-1·h-1) are the rate constants of pseudo-first- and second- order 
adsorption respectively. 
Time dependent adsorption data was collected for up to 72 hours at room temperature (23 
 1 oC). Results are shown in Figure 4.3 A. Kinetic data is found to be best fitted to the 
pseudo-second order model (𝑅2 > 0.99). The parameters, Qe and k2, derived for 
Equation 3 were determined to be 34.97 mg/g and 0.012 g·mg-1·h-1 respectively, the 
calculated adsorption time course curve is also shown in Figure 4.3 A, demonstrating the 
validity of the kinetic model. 
Isotherm data were fitted into Freundlich and Langmuir models. The linearized forms of 
these two models are shown in below [39,40]: 
Freundlich isotherm: 





where Ce is the equilibrium concentration of lysozyme (mg/L) in the solution, and kf 













where Qe (mg/g) is adsorbed lysozyme at equilibrium, Qm (mg/g) is the maximum 
adsorption amount at complete monolayer coverage, and b (L/mg) is the Langmuir 
constant representing the energy of adsorption. 
Fitting results are shown in Figure 4.3 B. Among the two adsorption isotherm models, it 
was found that the data fit well with the Langmuir model (R2=0.94) as shown by the line 
in Figure 3B.  The fitting parameters for the Langmuir isotherm were determined to be 
Qm=76.34 mg/g, b=0.0026 L/mg. The complete fitting parameters and curves for 





Figure 4.3 (A) Adsorption kinetics and (B) isotherm at 296 K. Error bars for some 
data points are too small to be displayed. The black square shows the experimental 
data, and the red dash curve shows the best-fit curve. Kinetic data is fit with 
pseudo-second order kinetic (R2 > 0.99). Isotherm data fits well with the Langmuir 
isotherm (R2 = 0.94).  
4.3.3 Protein/Peptide Release in the Absence of Cells  
SiNPs provided controlled release for both lysozyme and N-94 over the course of 8 
hours. Approximately 50% of the loaded lysozyme was released within the first 3 hours 
with complete release from SiNPs within 24 hours (Figure 4.4 A). N-94 exhibited a 
similar release profile (Figure 4.4 B). ~30% release was achieved within the first 3 hours, 






Figure 4.4 (A) Lysozyme release from SiNPs in PBS at pH 7.4 and 37 ℃ in the 
absence of cells. Lysozyme loading (i.e., 𝑴∞) was 21.74 ± 2.32 mg/g. (B) N-94 release 
from SiNPs, N-94 loading (i.e., 𝑴∞) was 44.94 ± 0.42 mg/g. SiNPs can providde 
controlled release for both lysozyme and N-94 over the course of 8 hours. 
Representative spectra of various masses (m/z or Da) of lacritin peptide (N-94) (C) 
prior to its conjugation to SiNPs, and (D) after release from SiNPs. The conjugation 
to SiNPs and release do not affect peptide integrity. 
The integrity of N-94 was maintained throughout its release. MALDI-TOF mass 
spectrometry of pre-conjugated N-94 (Figure 4.4 C) as well as N-94 that was released 
after being conjugated to SiNPs (Figure 4.4 D) revealed high intensity peaks of the full 
25-amino acid long peptide, both with FITC at 3400 Da and without FITC at 3000 Da. 
There were no peptide fragments of less than 3000 Da in either spectrum, indicating that 







4.3.4 Dissolution of SiNPs in the Absence of Cells 
SiNPs degradation was studied under physiological conditions in PBS for up to 30 days. 
Progress of the degradation process was monitored in terms of SiNPs diameters as a 
function of time using TEM (Figure 4.5). Results for Days 0, 10 and 30 were found to be 
113 ± 15 nm, 103 ± 20 nm and 98 ± 15 nm, respectively. One-way ANOVA confirmed 
that the size reduction of SiNPs was statistically significantly over the period of the 
experiment (P < 0.05). 
 
Figure 4.5 SEM images of SiNPs with an increasing immersion time in PBS, (A) t=0, 
(B) t=10 days, and (C) t=30 days. (D) Size variation of SiNPs after immersion in PBS 
for 0, 10, and 30 days. Each value is presented as mean ± SD. Based on the one-way 
ANOVA test, size of SiNPs significantly decreased with a prolonged immersion time 
(*, P < 0.05), indicating the degradation of the nanoparticles. 
4.3.5 Toxicity of N-94 to HCECs 
Toxicity of N-94 to HCECs was examined over a N-94 concentration range of 1–10 000 
nM for up to 24 hours and measured using cellular metabolic activity. Exposure of HCEC 
to N-94 up to the maximum peptide concentration and exposure time used did not result 
in significant changes in cellular metabolic activity (Figure 4.6).  






















Figure 4.6 Mean cellular metabolic activity (% relative to vehicle control ± SD) of 
primary human corneal epithelial cells obtained from three donors (N=3) following 
treatment of lacritin peptide (N-94) (1, 10, 100, 1000, 10 000 nM). Vehicle control 
(dotted line, 100%) was cell culture medium treatment only. MTT assays were 
performed after 1, 2, 6, and 24-hour treatment durations. There were no significant 
differences in cellular metabolic activity between the varying concentrations and 
durations of N-94 treatment, including vehicle control. 
4.3.6 Cytoprotective Effects of N-94 to HCECs 
The concentration of pro-inflammatory cytokines used to insult cells were first optimized 
to decrease cellular metabolic activity to 65–75% of that of “healthy” vehicle control 
cells to test the cytoprotective effects of N-94 (Figure 4.7 A). Treatment of HCECs with 
an insult combination of 100 U/mL IFNγ and 12.5 ng/mL TNF for 16 and 20 hours 
respectively decreased cellular metabolic activity to 74.80 ± 6.25% and 66.09 ± 1.92%. 
HCECs insulted with the optimized concentrations of IFNγ and TNF were co-treated with 
N-94 (Figure 4.7 B). Compared to insult only by IFNγ and TNF, there were significant 
increases in cellular metabolic activity when co-treated with 1 nM (P < 0.05) or 10 nM (P 
< 0.001) of N-94 after 20 hours. The effect of co-treatment with 100 nM and 1 000 nM 
N-94 on insulted HCECs were statistically non-significant. However, treatments of 10 




activity in comparison to insult only. This higher N-94 concentration was removed from 
the subsequent experiments that tested with N-94-SiNPs. 
 
Figure 4.7 . Mean cellular metabolic activity (% relative to vehicle control ± SD) of 
primary human corneal epithelial cells obtained from three donors (N=3) following 
(A) insult by 100 U/mL of IFNγ and varying concentrations of TNF (0, 6.25, 12.5, 25, 
50, 100 ng/mL) and (B) co-treatment of lacritin peptide (N-94) (0, 1, 10, 100, 1000, 
10 000 nM) along with insult by 100 U/mL IFNγ and 12.5 ng/mL TNF. In both, 
vehicle control (dotted line, 100%) was cell culture medium treatment only. MTT 
assays were performed after 16- and 20-hour treatment durations. *, **, and *** 





4.3.7 Toxicity of N-94-SiNPs to HCECs 
HCECs were treated with the mixture containing SiNPs, released N-94, and any potential 
dissolution products of SiNPs. Statistical analysis showed no significant differences in 
cellular metabolic activity between treatments of any concentration of N-94-SiNPs up to 
1 000 nM or SiNPs and vehicle control at 16 and 20 hours (Figure 4.8 A). There were 
also no significant differences in LDH release between treatments of any concentration of 
N-94-SiNPs up to 1 000 nM or SiNPs and vehicle control at either time point (Figure 4.8 
B).  
 
Figure 4.8 (A) Mean cellular metabolic activity (% relative to vehicle control ± SD) 
and (B) mean lactate dehydrogenase (LDH) release (% relative to vehicle control ± 
SD) of primary human corneal epithelial cells obtained from three donors (N=3) 
following treatment of lacritin peptide-conjugated silica nanoparticles (N-94-SiNPs) 
(1, 10, 100, 1000 nM). There was a vehicle control (dotted line, 100%) of phosphate-
buffered saline and cell culture medium treatment only and a group of bare SiNP 
treatment only. MTT and LDH assays were performed after 16- and 20-hour 
treatment durations. There were no significant differences in cellular metabolic 
activity and LDH release between the various treatments and vehicle control at 






4.3.8 Cytoprotective Effect of Released N-94 on Stressed HCECs 
Compared to insult only, treatment equivalent to 1 nM of released N-94 significantly (P < 
0.05) increased the cellular metabolic activity of insulted cells at 16 and 20 hours while 
10 nM of released N-94 significantly (P < 0.001) increased the cellular metabolic activity 
of insulted cells at 20 hours (Figure 9A). Compared to insult only, co-treatment with 10 
nM (P < 0.01) and 1000 nM (P < 0.05) of released N-94 significantly reduced the LDH 
release of HCECs at 20 hours (Figure 4.9 B). 
 
Figure 4.9 (A) Mean cellular metabolic activity (% relative to vehicle control ± SD) 
and (B) mean lactate dehydrogenase (LDH) release (% relative to vehicle control ± 
SD) of primary human corneal epithelial cells obtained from three donors (N=3) 
following co-treatment of lacritin peptide (N-94) (0, 1, 10, 100, 1000 nM) released 
from silica nanoparticles along with 100 U/mL IFNγ and 12.5 ng/mL TNF. Vehicle 
control (dotted line, 100%) was phosphate-buffered saline and cell culture medium 
treatment only. MTT and LDH assays were performed after 16- and 20-hour 
treatment durations. *, **, and *** indicate statistical significance versus insult 







The Stöber process provides a facile pathway towards the synthesis of fairly uniform 
SiNPs using the silica precursor TEOS [36].  Uniformity in size (Figure 4.1) allows for 
precise drug loading. SiNP size can be tuned as a function of reaction pH and 
temperature. SiNPs in the size range of 100-400 nm are promising for drug delivery 
applications, as they render a sufficient surface area to volume ratio to enable a high 
loading and would not induce significant cytotoxicity [16]. 
Lysozyme loading onto SiNPs is demonstrated by both SEM and FTIR. Aggregation of 
lysozyme can be seen which has been attributed to lysozyme-SiNP interaction on the 
particle surface [41]. Lysozyme conjugation to SiNPs is further confirmed by the FTIR 
spectrum (inset, Figure 4.2 A). For lysozyme, the amide I peak intensity is low at 1649 
cm-1, likely due to its low concentration relative to the SiNPs, but its presence serves as 
direct evidence of successful conjugation of lysozyme to SiNPs [42]. The amide II peak 
at 1550 cm-1 was not observed due to its lower intensity compared to the amide I peak 
[43].   
Results of adsorption experiments over a 72-hour period are shown in Figure 3A. The 
results indicated that equilibrium adsorption was attained at around 45–50 hours. At the 
early stage (0–12 hours), adsorption was fast due to the high concentration of lysozyme 
and the number of binding sites. As adsorption proceeded, the rate slowed down, possibly 
due to the depletion of lysozyme and occupation of binding sites [40].  
Pseudo-second order kinetics suggests that chemisorption is the rate controlling step 
throughout the adsorption process [44], the adsorption of lysozyme on SiNPs is most 
likely a combined effect of both physical and chemical interactions.  
Equilibrium loading capacity is an important parameter in assessing the suitability of 
SiNPs as a carrier for the controlled release of a protein for therapeutic applications as it 
can be used to determine the maximum loading capacity for the release of a protein 
within the therapeutic dose range by a carrier. Among the several models available, the 




[41,45,46]. This adsorption isotherm assumes monolayer adsorption with minimal 
interaction among the adsorbate molecules. With macromolecular proteins such as 
lysozyme with surface functional groups, the process is more complex. The difference 
IEPs between SiNPs (IEP ~3.0) and lysozyme (IEP=10.9) would lead to the adsorption of 
positively charged protein onto SiNPs, resulting a protein monolayer on the surface 
SiNPs [38,47]. The existence of intermolecular repulsive electrostatic interactions will 
prevent second layer of adsorption.  The maximum monolayer adsorption capacity (Qm) 
of lysozyme on silica nanoparticles typically falls in the range of 50-520 mg/g, depending 
on the pH and ionic strength, with the greatest Qm achieved at a pH near the IEP of 
lysozyme in the absence of electrolyte [46,48]. The deviation from this maximum loading 
could be explained by the salts in PBS and the suboptimal loading pH. 
The release process of cargo is governed by the concentration gradient of the 
protein/polypeptide at the SiNPs surface followed by its rapid diffusion into the medium 
(Figure 4.4 A and B). This type of release profile makes this system a promising 
candidate in the topical treatment of aliments such as DED which require relatively rapid 
drug release at the target site that is still sustained for a few hours. The release rate can be 
tuned by varying the initial protein loading on the SiNPs or by silica surface modification 
for other clinical applications. In contrast to the lysozyme-SiNP system where all the 
adsorbed protein was released over time, only about half of the N-94 was released from 
the N-94-SiNPs. N-94 is a much smaller and flexible molecule than lysozyme. This could 
allow for more than one conformation of the adsorbed N-94. The relative stability of 
these conformations could lead to the incomplete release observed. This could be a 
concern that has to be addressed in the design and development of a N-94-SiNP treatment 
system for DED. Nevertheless, the molecular integrity of N-94 was retained during the 
release, as demonstrated by the MALDI results. Overall, the sustained delivery of N-94 
can increase its bioavailability when applied to the cornea as compared to the current 
drop treatment approach.  
The SiNPs degradation was evident from the time dependent change of the particle 
diameter. The degradation rate of SiNPs can been tuned to meet the requirements of a 




particles have higher degradation rates [49]. The ultimate dissolution time in vivo is 
dependent on the particle size, synthesis method, and the properties of fluid it is subjected 
to [49,50]. The degradation of the material is favorable for drug delivery application as 
the carriers serve no other useful purposes after the therapeutics are delivered. 
The clinical significance of the N-94-SiNP delivery system was supported by 
experiments demonstrating that neat N-94 was non-toxic to HCECs and can effectively 
reduce cell damage imparted by pro-inflammatory cytokines across a wide time and 
concentration range (Figure 4.7 B). We found that release products from N-94-SiNPs 
were non-cytotoxic, and N-94 released from SiNPs remained cytoprotective (Figure 8 
and 9). We observed optimal cytoprotective effects at 10 nM and potentially 1 nM. This 
corroborates existing lacritin studies that determined a 10 nM optimal concentration for 
cytoprotective effects on HCECs and a 1–10 nM optimum for bactericidal activity 
[29,30]. We applied N-94 for 16 and 20 hours to check cytoprotective effects over a long 
period of cell stress and found that an exposure to 10 nM of N-94 for 20 hours was most 
effective in our model. It is possible that the autophagy pathway that restores homeostasis 
during inflammation was gradually triggered by increasing amounts of N-94 binding 
syndecan-1 on the HCECs, reaching an optimum at 20 hours [29].  
A limitation in the translatability of our study is the gap between the complete release of 
N-94 from SiNPs after 8 hours and its optimal cytoprotective effects at 20 hours after 
release. As mentioned, it may be worthwhile to study release kinetics in a solvent 
containing tear proteins such as lacritin to possibly prolong release. Treating cells with 
the conjugated N-94-SiNPs without first inducing release would also be useful in 
studying optimal treatment durations once release kinetics are established in tear-
mimicking cell culture media. Future studies should also extend the study duration: 
supplementing with additional N-94 daily as it is depleted can mimic daily drug 
administration. In addition, other cell models could be explored to investigate the 
preventative effect and rescue ability of N-94. More specifically, pre-treating HCECs 




Trans-well inserts were used to separate N-94-SiNPs from HCECs to avoid the 
endocytosis of SiNPs [17]. In clinical application, it must be ensured that the N-94-SiNPs 
can remain on the ocular surface for the entire duration of N-94 release. This challenge 
presents opportunities to create novel approaches for implementation. Future studies 
could explore a secondary drug carrier for our proposed drug delivery system, such as 
silicone hydrogel contact lenses. Embedding N-94-SiNPs into contact lens would further 
ensure sustained drug delivery. While hydrogel contact lens itself can be considered as a 
primary drug carrier, the SiNPs intermediate confers flexibility: it may be difficult to 
synthesize different types of complex hydrogen matrices personalized for different 
amounts of drug release, but we can more easily vary the amount of SiNPs embedded 
into contact lenses for patients with varying degrees of dry eye. 
4.5 Conclusions 
As an excellent option for bioactive protein and peptide delivery, the SiNP-based 
delivery system mediated the controlled release of cargo for a period of eight hours. This 
type of release profile could be useful in dry eye treatment, as it could allow patients to 
encounter the drug-elution at night, ideally while sleeping, and then to have 16 hours of 
relief during waking hours. We have demonstrated that N-94 is functionally equipotent to 
its parent protein lacritin and cytoprotective of stressed HCECs in its free dosage form. 
The constitution of the N-94-SiNP delivery system successfully retained the peptide’s 
molecular integrity and biological functionality. The peptide carrier was degradable and 
was non-toxic to cells. The system has potential for incorporation into other ophthalmic 
devices such as silicone hydrogel contact lens or new multifunctional devices. Overall, 
the N-94-SiNPs delivery system represents a promising approach that can be further 
developed for the treatment of DED.  
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Chapter 5  
5 Development of Multifunctional PVA-SiO2-IONP 
Microparticles for TACE3 
5.1 Introduction 
Drug-eluting microparticles are characterized as matrix systems in which the drug is 
homogeneously dispersed, either in dissolved or suspended form [1]. These micron-sized 
delivery packages hold great utility in the clinical management of numerous diseases. 
Plentiful microparticles composed of biocompatible polymers, such as chitosan, alginate, 
poly(vinyl alcohol) (PVA) and poly(lactic-co-glycolic acid) (PLGA) were developed for 
treating gastric diseases, lung cancer and hepatocellular carcinoma (HCC) [2–4]. Such 
particles could be prepared via a wide array of processing techniques, including 
microfluidics, electrospray and spray drying [1,5,6]. In addition to being used solely, 
such particles can be used as a component in existing platforms, such as microfibers, 
scaffolds, or bulk hydrogels for many applications, including drug delivery and tissue 
regeneration [7–10]. 
Multifunctional drug-eluting microparticles have been a center of research in the past 
decade. Such particles can fulfill two or more functions after administration, making 
them promising in treating complex systems, such as tumors [11]. Targeted drug delivery 
can localize the drug to the site of action, minimizing the unwanted toxicity to healthy 
tissue [12]. Controlled release capability can avoid burst release and maintain an effective 
drug concentration for a prolonged time [13,14]. Degradation of the delivery system is 
beneficial as drug release can be modulated by the degradation rate of the carrier. In 
addition, device removal is not required. Repeatable treatment is possible because the 
carriers can be broken down into innocuous products and eliminated from the body after 
the therapeutic is depleted [15]. Furthermore, imageable drug carriers facilitate the 
 
3 A paper under the title: Microfluidic fabrication of drug-eluting composite hydrogel microparticles is in 




diagnosis and postoperative feedback, which is particularly advantageous in 
interventional radiology for cancer treatment [16].  
Composite hydrogels provide a powerful platform to construct multifunctional drug-
eluting systems. The idea behind it is to use nanoparticle fillers, biological factors, or a 
combination of polymers to enhance and diversify the properties of traditional hydrogels 
[17,18]. Poly(vinyl alcohol) (PVA) is one of the most commercially important 
biocompatible polymers in use. PVA can be stabilized via physical crosslinking through 
the freezing-thawing technique, in which no toxic chemical crosslinkers are required. The 
porosity and mechanical properties can be altered by adjusting the process parameters, 
polymer concentration in the solution and molecular weight of PVA [19]. The non-toxic 
crosslinking approach, along with the tunable properties, renders PVA widespread 
biomedical applications, including drug delivery, wound dressing and orthopedic 
implants [20]. Iron oxide nanoparticles (IONPs) have gained particular interests due to 
their excellent magnetic properties, making them good candidates as magnetic resonance 
imaging (MRI) contrast agents and drug carriers for targeted delivery [21].  Furthermore, 
the incorporation of IONPs into the PVA could endow the system with degradability. 
Bannerman et al. introduced IONPs to the PVA hydrogels through in situ co-precipitation 
[22]. IONPs were allowed to form hydrogen bonding with PVA chains and participate in 
hydrogel crosslinking during the subsequent freezing-thawing cycles. As a result, the 
gradual dissolution of IONPs in an acidic environment would weaken the linkages, and 
therefore the stability of the matrix, leading to the ‘degradation’ of PVA. Silica (also 
known as silicon dioxide, SiO2) has been "generally recognized as safe" by the FDA for 
more than five decades and is widely used in the food industry as a color or formulation 
stabilizer [23,24]. The presence of abundant surface silanols (Si-OH) allows the 
conjugation to various organic functional groups, rendering silica nanoparticles (SiNPs) 
with a wide range of applications in disease diagnosis and controlled drug release [25]. In 
addition to SiNPs, silica-based materials in the form of composite hydrogels have 
attracted significant attention. For example, silica-PVA hydrogels derived from acid-
catalyzed sol-gel synthesis possess improved permeability and mechanical properties 
compared to neat PVA hydrogels [26–28]. It is speculated that the relatively slow 




participate in hydrogen bonding with the hydrogel polymers [29]. The formation of 
silica-hydrogel interaction affects the intramolecular binding of the polymeric chains and 
could reduce the crystallinity while improving the PVA's diffusivity [27,30]. This 
improvement is particularly beneficial for drug delivery as it would facilitate the 
permeation of drug molecules [31,32].  
In this chapter, we continued the previous work on multifunctional PVA-IONP 
microparticles (Chapter 3). However, we introduced silica to the composite hydrogel to 
modify the loading and release ability of the delivery system. This material was prepared 
via the acid-catalyzed sol-gel process and in situ co-precipitation. The microparticulate 
PVA-SiO2-IONP system was fabricated by microfluidics and stabilized by the low 
temperature thermal cycling (LTTC). The detailed scheme of the preparation of the 
particles is presented in Figure 5.1. Various flow rates of the continuous phase and 
dispersed phase were explored to make microparticles of adjustable sizes. The resulting 
PVA-SiO2-IONP microparticles were comprehensively characterized in the aspects of 
morphology, composition, magnetic properties, drug loading/release and degradation. 
This multifunctional delivery system can potentially be used as drug-eluting 
microparticles in different interventional radiology therapies, such as transarterial 








Figure 5.1 Schematic illustration for the preparation of PVA-SiO2-IONP 
microparticles. 
5.2 Materials and Methods 
5.2.1 Materials 
PVA (MW 146,000-186,000, 99+% hydrolyzed), iron (III) chloride (FeCl3), iron (II) 
chloride tetrahydrate (FeCl2•4H2O) were purchased from Sigma-Aldrich. 
Tetraethylorthosilicate (TEOS, 99+%) was acquired from Alfa Aesar. Hydrochloric acid 
(36.5%-38%, HCl) was obtained from Caledon. Sodium hydroxide (NaOH) pellets were 
purchased from ThermoFisher Scientific. Doxorubicin hydrochloride was obtained from 
Cayman Chemicals. Span80 was purchased from Fluka. Ethanol (95%) was acquired 
from Commercial Alcohols. Phosphate buffer solution (pH 5.5) was prepared by a 
procedure reported elsewhere [33]. All other chemicals were purchased from Sigma-
Aldrich and were used without any purification. 
5.2.2 Preparation of PVA Solution 
A 2.99 wt% PVA solution was prepared at 90 °C under mechanical stirring (rpm 100). 
The temperature was maintained for at least 3 h. The PVA was stored at room 




5.2.3 Preparation of Iron Chloride Solution 
An iron chloride solution containing 20.66 wt% FeCl3 and 12.66 wt% FeCl2∙4H2O (2:1 
molar ratio) in distilled water was prepared at room temperature. 
5.2.4 Preparation of PVA-SiO2-Fe (II, III) Gel 
First, a silica sol was prepared by slowly adding 2.76 mL TEOS into a solution 
containing 2.7 mL of H2O, 2.95 mL of ethanol and 70 µL concentrated HCl. The 
resulting mixture was maintained at 60 °C under magnetic stirring (rpm 150) for one 
hour. To prepare the PVA-SiO2 gel, 1.36 g of silica sol was mixed with 13.64 g 2.99 wt% 
PVA solution. The resultant gel was then aged at 60 °C under magnetic stirring (rpm 
150) for five hours. The PVA-SiO2 gel, after cooling, was blended with 2.78 g iron 
chloride solution. The resulting PVA-SiO2-Fe (II, III) gel was filtered through a 5 μm 
filter (Acrodisc® syringe filter, Pall Laboratory) and stored at room temperature. 
5.2.5 Fabrication of the Flow-focusing Microfluidic Device 
A planar microfluidic system, comprising a flow-focusing configuration, was prepared 
using poly(methyl methacrylate) (PMMA) slab (50 x 25 x 12 mm) by milling. The width 
of the continuous phase and dispersed phase channels were 500 m and 200 m, 
respectively. A second PMMA slab (50 x 25 x 12 mm) was sealed onto the channel slab 
by screws. Two needles (20 gauge, Hamilton Company) attached with silicone tubes 
(0.062 x 0.125’’, VWR International) were inserted into the inlet of the top slab to allow 
independent injection of continuous phase and dispersed phase at selected rates 
controlled by two syringe pumps (NE-1000, New Era Pump Systems Inc.). The droplets 
generated were directed into a NaOH tank through an outlet tubing (0.023 x 0.038’’, 
IntramedicTM PE tubing, BD). 
5.2.6 Fabrication of PVA-SiO2-IONP Microparticles 
Undecane containing 1 wt.% Span80 was used as the continuous phase, while the PVA-
SiO2-Fe (II, III) gel was used as the dispersed phase. Microparticles were fabricated at 
various flow conditions. The microfluidic fabrication was first conducted at a fixed 




(Qd=1-9 mL/h). Subsequently, the fabrication was conducted at two different Qd’s (Qd=1 
mL/h and 3 mL/h) with various continuous phase flow rates (Qd=5-45 mL/h). The 
produced droplets were collected in a reservoir containing 1.0 mol/L NaOH for 
solidification. The resulting PVA-SiO2-IONP microparticles were collected and 
thoroughly cleaned by 50 v/v% ethanol.  
In later experiments (section 5.2.7-5.2.14), dispersed phase (Qd=3mL/h) was focused by 
the continuous phase (Qc=20 mL/h). The droplets were guided into NaOH, collected and 
washed as stated before. The cleaned microparticles were subsequently placed into a 
programmed cryobath for three freeze-thaw cycles (FTCs) (from 20°C to -20°C then to 
20°C at 0.1°C/min, held for one hour at the temperature limits). The microbeads were 
stored in phosphate buffered saline (PBS) at room temperature until future use. 
5.2.7 Drug Concentration Effect on DOX loading 
Doxorubicin (DOX) was loaded into microparticles by immersion approach.  Briefly, 
0.25 mL microparticles were added into 1 mL of DOX stock solution of various 
concentrations (C0=0.125 mg/mL, 0.25 mg/mL and 0.50 mg/mL) under mild shaking 
condition overnight. Afterwards, the loading solution was retrieved and subject to UV-vis 
measurements (Cary 60 UV-Vis, Agilent Technologies Inc.) at 485 nm. The drug-loaded 
microbeads were carefully washed with PBS to remove the surface-associated DOX. 




) = (W0 − Wt)/V b 
(1) 
Loading efficiency was determined according to Equation 2: 
Loading efficiency (%) =
(W0−Wt)
W0
× 100% (2) 
where W0 is the initial amount of DOX in solution, Wt is the amount of DOX in the 
supernatant, and Vb is the volume of hydrated PVA-SiO2-IONP beads in each sample. 




5.2.8 In vitro Release of DOX 
The in vitro release profiles of DOX from PVA-SiO2-IONP microbeads were studied in 
three release media at 37 °C with shaking at 110 rpm (shaking water bath, New 
Brunswick Scientific). Microparticles with various DOX loading (i.e., C0=0.125 mg/mL, 
0.25 mg/mL and 0.50 mg/mL) were added into 15 mL corresponding release media (PBS 
pH 7.4, phosphate buffer pH 5.5 and acidic water pH 5.5). At predetermined time 
intervals, 1 mL of liquid was retrieved from each sample, and 1 mL of fresh media was 
replenished. The DOX concentration in the liquid was quantified, as stated before. 
5.2.9 Degradation of PVA-SiO2-IONP Microparticles 
The degradation of microbeads was studied at 37 °C in PBS and phosphate buffer. In 
detail, 0.25 mL blank PVA-SiO2-IONP microbeads were incubated with 15 mL 
corresponding buffer. The degradation medium was replaced with a fresh one every 5 
days. At designated time points, samples were retrieved and dried for microscopic 
imaging. 
5.2.10 Size Analysis 
The size of microparticles was measured by an optical microscope (Olympus BX60) 
coupled to an OMRX A35100U camera. Samples were prepared by dropping microbeads 
suspension on the microscope glass slides. The sectional area of the beads was measured 
manually using Image J software for over 100 samples and then converted into an 
equivalent spherical diameter using Equation 3:  
d = 2√A/π 
 
(3) 
where d is the equivalent spherical diameter and A is the measured sectional area of the 
microbead. Results are expressed as the mean ± standard deviation of more than 100 




5.2.11 Scanning Electron Microscopy (SEM)/Energy-Dispersive X-
ray (EDX) 
Samples were critical point dried (K850 Critical Point Dryer, Electron Microscopy 
Sciences) and fixed on a carbon tape. A layer of 5 nm osmium coating was sputtered onto 
the surface of the samples using a plasma coater (OPC80T, Filgen) before imaging. 
Scanning electron micrographs and elemental mapping were obtained using an SEM 
coupled with energy EDX spectroscopy (LEO (Zeiss) 1540XB FIB/SEM). 
5.2.12 Transmission Electron Microscopy (TEM) 
To visualize the silica particles, silica sol was properly diluted using water, sonicated and 
dripped onto a Formvar carbon-coated 400 mesh copper grid (Electron Microscopy 
Sciences), air-dried and observed under TEM (CM10, Philips). 
The internal structure of PVA-SiO2-IONP microbeads was analyzed using TEM. Samples 
were dehydrated in acetone and embedded in epoxy resin. After that, embedded beads 
were ultramicrotomed (Reichert-Jung Ultracut E) with a diamond knife and the resulting 
slices were placed on copper grids (Electron Microscopy Sciences) for imaging at 80 kV. 
5.2.13 Fourier Transform Infrared Spectroscopy (FTIR) 
The samples of neat PVA, PVA-SiO2 gel and PVA-SiO2-IONP microparticles were dried 
in an oven at 60 °C overnight. FTIR analysis (Perkin-Elmer, Massachusetts, USA) was 
then performed in the region of 4000-500 cm-1 at a resolution of 2 cm-1. 
5.2.14 Vibrating Sample Magnetometry (VSM) 
PVA-SiO2-IONP microparticles were oven-dried at 60 °C overnight. The magnetization 
curve of the microparticles was obtained using a vibrating sample magnetometer 
(LakeShore 7407, Lake-ShoreCryotronics Inc.) at 298 K. 
5.2.15 Statistical Analysis 
For DOX loading and release experiments, a sample size of three or nine was used for 




condition. Statistical analysis was performed using Microsoft Excel and GraphPad Prism 
v9 (La Jolla, CA). Results are reported as the mean ± standard deviation.  
5.3 Results 
5.3.1 Microfluidic Fabrication of Size-tunable PVA-SiO2-IONP 
Microparticles 
The flow-focusing microfluidic device was effective in producing tadpole-shaped PVA-
SiO2-IONP microbeads with tunable sizes (129-272 𝜇m). The polydispersity index (PDI), 
defined as the ratio between the standard deviation and the mean diameter of particles 
multiplied by 100, was calculated for each flow condition. The droplets developed PDI 
values ~10%, suggesting that a reasonably monodisperse population [34,35]. 
 
Figure 5.2 Relationship between particle diameter and flow rates. (A) Diameter as a 




of continuous phase, Qd=1 mL/h, 3 mL/h, Qc=5-45 mL/h. (C)-(E): Optical 
microscope images and size distributions of microbeads fabricated under different 
flow rate conditions. For a fixed Qc=20 mL/h, the particle size decreased first and 
then increased as the Qd increased. At a fixed Qd, the particle size decreased with an 
increased Qc. 
5.3.2 Characterization of PVA-SiO2-IONP Microparticles 
The morphology of PVA-SiO2-IONP microbeads was shown in Figure 5.3 A. The EDX 
analysis (Figure 5.3 D) confirmed the co-existence of iron oxide and silica throughout the 
microparticles.  
 
Figure 5.3 (A) and (B): surface morphology of microparticles (Qd=3 mL/h, Qc=20 
mL/h). (C) and (D): EDX spectrum of microparticles with a square indicating the 
area of analysis. (E) is the EDX elemental mapping of the entire sample in (C). The 








The silica and iron oxide components were visualized by TEM (Figure 5.4). Silica 
microparticles were found in a spherical shape with a diameter of 1.3 ± 0.5 𝜇m. IONPs 
were well dispersed in the PVA matrix. The diameter of IONPs was measured to be 2.3 
± 0.8 nm.  
 
Figure 5.4 TEM images of (A) silica sol and (B) PVA-SiO2-IONP microbeads. Acid-
catalyzed sol-gel process contributed to spherical silica microparticles with a 
diameter of 1.3 ± 0.5 𝝁m. IONPs were 2.3 ± 0.8 nm in diameter and were well-
dispersed in the microbeads. Due to the large variance of the dimension of silica 
microparticles and IONPs, individual silica microparticle cannot be displayed in (B) 
with IONPs. 
The FTIR spectrum of neat PVA, PVA-SiO2 gel, PVA-SiO2-IONP microparticles were 
shown in Figure 5.5. The neat PVA sample showed characteristic bands at 3220 cm-1, 
2897 cm-1 and 1078 cm-1 due to the O-H stretching, C-H stretching, and C-O-C, 
respectively [36].  
The PVA-SiO2 composite gels showed a new band at 946 cm-1, attributed to the Si-OH 
stretching [37]. The spectra in the range of 1040-1100 cm-1 indicated the co-existence of 
C-O-C, Si-O-Si and C-O-Si stretching [36,37]. The increase in the width of the peaks and 
its slight shift towards a lower wavenumber could be associated with the formation of Si-
O-Si groups (~1060 cm-1) and intermolecular reaction between TEOS and PVA (C-O-Si 
stretching, 1080-1120 cm-1) [37,38]. This hypothesis was supported by the considerable 




condensation reaction between the hydroxyl groups from silicate (i.e., silanol groups) and 
PVA [39].  Compared with the O-H bands (3220 cm-1) of PVA and PVA-SiO2 gels, an 
increase in the width of O-H band after IONPs incorporation was observed for PVA-
SiO2-IONP beads, indicating a possible formation of intermolecular bonding between the 
IONPs and PVA through hydroxyl groups.  
 
Figure 5.5 FTIR spectra of neat PVA, PVA-SiO2 gel, and PVA-SiO2-IONP 
microbeads. The emergence of C-O-Si peak and reduction of O-H peak indicates the 
condensation reaction between -OH groups of PVA and surface silanols of silica. 
To characterize the magnetic properties of the delivery system, VSM was performed on 
the PVA-SiO2-IONP microparticle sample. The magnetization curve (Figure 5.6 A) 





Figure 5.6 Magnetization curve of PVA-SiO2-IONP microparticles. The 
microparticles exhibited paramagnetic behavior. (B) Microparticles dispersed in 
PBS attracted by a permanent magnet. 
5.3.3 Drug Concentration Effect on DOX Loading 
PVA-SiO2-IONP microparticles were incubated with DOX solution of 0.125 mg/mL, 
0.25 mg/mL and 0.50 mg/mL, the results of drug loading were summarized in Table 5.1. 
A higher loading while lower entrapment efficiency was observed when a more 
concentrated DOX stock solution was used. The DOX loading was 0.45 ± 0.03, 
0.79 ±  0.08 and 1.34 ± 0.09 mg/mL, respectively. Under these loading conditions, the 
entrapment efficiency was 89.8 ± 6.6%, 79.3 ± 7.9% and 66.9 ± 4.5%, respectively.  
Table 5.1 Drug concentration effect on DOX loading. 
 
5.3.4 In vitro Release of DOX 
Figure 5.7 shows the release profile of PVA-SiO2-IONP microparticles with various 
DOX loading (i.e., 0.45 ± 0.03, 0.79 ±  0.08 and 1.34 ± 0.09 mg/mL) in different 





observed afterwards. The release plateau was reached at 7 days for all subgroups. Within 
the same DOX loading group, the release rate increased with a higher ionic concentration 
in buffer or a lower pH value.  
The loading effect on DOX release was illustrated in Figure 5.7 D. PVA-SiO2-IONP 
microspheres with a higher loading rendered a slower release. At day 21, the cumulative 
release for microspheres with 0.45 ± 0.03, 0.79 ±  0.08 and 1.34 ± 0.09 mg/mL loading 
were 44.94 ± 0.88%, 45.33 ± 2.82% and 33.50 ± 1.62%, respectively.  
 
Figure 5.7 In vitro drug release from DOX-loaded PVA-SiO2-IONP microparticles: 
(A)-(C) effect of release conditions on DOX release; (B) effect of drug loading on 
DOX release. Within the same DOX loading subgroup, the release rate increased 
with a higher ionic concentration in buffer or a lower pH value. At the same buffer 
condition, microparticles with a higher DOX loading contributed to a slower and 
lower percentage of release. 
5.3.5 Degradation of Microparticles 
The degradation of microparticles was evidenced by the morphological change during the 
test period (Figure 5.8). PVA-SiO2-IONP microbeads degraded faster in acidic phosphate 
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buffer than in PBS, as the uneven surface and deformation of the original tadpole shape 
were more apparent from SEM images.  
 
Figure 5.8 SEM images of the PVA-SiO2-IONP microparticles at two buffer 
conditions. Pictures were obtained after 0, 14, 35 and 56 days’ immersion in the 
corresponding buffer. Error bar: 20 𝝁m, except for day 14 PBS (error bar 100 𝝁m). 
The degradation of microparticles at both buffer conditions was evidenced by the 
morphological change during the test period. 
5.4 Discussion 
5.4.1 Microfluidic Fabrication of Size-tunable PVA-SiO2-IONP 
Microparticles 
During the microfluidic fabrication process, a dispersed fluid composed of PVA, SiO2 
and iron oxide precursors was sheared by the two continuous oil streams at the junctions 
of three microfluidic channels to form droplets. The resulting droplets were directed into 
the NaOH bath, where ferric and ferrous iron salts co-precipitate to form magnetite 
(Fe3O4) nanoparticles. The co-precipitation reaction can be represented by:  











The flow rate of the dispersed phase and continuous phase are important parameters in 
determining the diameter of the microbeads. The size of the droplets decreased with an 
increased Qc at a fixed Qd, which was consistent with the literature [283,297]. It has been 
reported that within a certain Qc range, a greater Qc value would result in more rapid 
thread collapse and the breakup of the dispersed phase, leading to a reduced particle size 
[42]. The literature also suggests that the increase in Qd will increase the size of 
microparticles [40], which was partially contradicted to our results, where the particle 
diameter first decreased with a larger Qd. When Qd exceeded the threshold value (i.e., 3 
mL/h), larger microparticles with broader size deviation were generated. The initial 
downward trend could be resulted from the instability of droplet breakup at the early 
operating conditions or the transition of breakup pattern (e.g., from dripping to jetting) 
[43]. However, the droplet generation process must be microscopically examined along 
with the computation of relevant parameters (i.e., capillary number and Weber number) 
to fully understand fluid mechanics and the effect of flow rates on the size of final 
droplets [42,44].  
The tadpole shape of PVA-SiO2-IONP microparticles could be attributed by the 
solidification process that emerged at the oil phase/NaOH interface. In the NaOH 
collection bath, the continuous phase (i.e., oil phase) would form a separate layer on the 
top of the NaOH phase with extended fabrication time. It was speculated that during the 
slow passage of PVA-SiO2-Fe (II, III) droplets through the oil phase/NaOH interface, the 
droplets deformed into tail shape due to the combined effect of gravity, interfacial 
tension, impact and tangential stress [45,46]. The co-precipitation of iron precursors 
proceeds in the presence of PVA and gradually increased the rigidity of microgel, which 
would prevent further changes in particle morphology. Indeed, non-spherical hydrogel 
microparticles are expected in droplet generation with a subsequent “external gelation” 
procedure. Alginate microparticles with different tailed morphologies have been 
intentionally produced by changing the viscosity of the polymer solution, the 
concentration of the crosslinker and collecting distance [47,48].  
Monodisperse, size-controlled and tail-shaped PVA-SiO2-IONP microparticles are 




facilitate the catheter delivery, which could potentially avoid the off-target embolization 
and allow a more proximal occlusion [49,50]. The non-spherical microparticles render a 
higher surface area compared to spherical ones, which makes faster drug release possible 
[48].  
5.4.2 Characterization of PVA-SiO2-IONP Microparticles 
Silica microparticles were formed in the acid-catalyzed sol-gel process. The reaction is 
generally carried out through simultaneous or successive reactions of hydrolysis and 
polycondensation of silica precursors in the presence of an organic cosolvent [29]. The 
net reactions can be described by:  
Hydrolysis: ≡Si-OR + H2O ⇌ ≡Si-OH + R-OH 
 
(5) 
Polycondensation: ≡Si-OH + HO-Si≡ ⇌ ≡Si-O-Si≡ + H2O (6) 
The size of generated silica particles was found to be similar to what was developed 
using the acidic catalysis procedure [51] but much larger than the particles derived from 
basic conditions [52]. The large diameter and broad size distribution can be explained by 
the gel formation scheme. In an acid-catalyzed sol-gel procedure, the hydrolysis rate is 
greater than the condensation rate. The silica tends to form linear polymeric networks that 
are occasionally crosslinked. In contrast, hydrolysis is a lot faster than condensation 
under basic conditions, which results in uniform and discrete silica particles [29].  
The incorporation of silica into the PVA is beneficial as it can potentially improve the 
drug loading and release capability of the delivery system. In a hydrogel-based delivery 
system, the microscopic structure of the polymeric network governs inward and outward 
molecular diffusion [53]. It was believed that the crystalline regions of polymers are 
impermeable to solutes [30,31]. This was supported by the reduction in diffusion 
coefficients through PVA gels with a greater degree of crystallinity or denser polymeric 
network.  Moreover, PVA with a denser network has stronger intermolecular interactions 
displays a smaller degree of swelling and, therefore pore expansion. This was believed to 
hinder drug penetration and release from the PVA matrix. The incorporation of silica 
components could reduce the density of polymer mesh and the degree of crystallinity, 




incorporation of silica nanoparticles (SiNPs) can interact with -OH groups from PVA and 
interfere with the PVA chain arrangement, which would diminish the crystallinity of 
PVA and contribute to an improved solute permeability [26–28].  
TEM micrographs confirmed the formation of well-dispersed and relatively uniform 
IONPs (D=2.3 ± 0.8 nm). The ultrasmall size (<50 nm) and good dispersity could be 
attributed by the protective effect of PVA [57]. In a study conducted by Lee et al., IONPs 
of average diameter 4-7 nm were synthesized via in situ co-precipitation. The ferric and 
ferrous ions co-precipitate in the PVA solution, during which PVA irreversibly adsorbed 
on the surface of IONPs [58]. It was hypothesized that the interaction of PVA hydroxyl 
groups with IONPs could protect the nanoparticles from growth and aggregation through 
steric stabilization [59,60]. 
The formation of IONPs within the microparticles is desirable for their applications as 
DEBs. First, IONPs could contribute to the crosslinking of the hydrogel and allow the 
delivery system to ‘degrade’ [22]. IONPs could provide contrast enhancement to 
magnetic resonance (MR) images [61]. More importantly, the co-localization of the 
contrast agent with drug contributes to more definitive and precise location of the drug, 
which could be useful for intraprocedural guidance and post-operative assessment. 
Moreover, the IONPs endow the microparticles with magnetic properties, making them 
promising in magnetically-guided drug delivery [62].  
The PVA-SiO2 interaction was revealed by the FTIR spectrum. Through the acidic 
hydrolysis of TEOS in the presence of PVA, the silanol groups not only condense with 
each other but also react with the hydroxyl groups of PVA to form C-O-Si bonds 
[26,39,63]. This PVA-SiO2 interaction could be desirable as it would affect the overall 
crosslinking of the hydrogel and render a more drug-permeable matrix. The contribution 
of SiO2 to the PVA crosslinking should also be considered for the degradation process.  
Compared with the O-H peak of PVA-SiO2 samples, the PVA-SiO2-IONP gave a peak 
with a weaker intensity and broader width. This could be attributed by the consumption 
of -OH groups during the crosslinking between PVA and IONPs [22]. Furthermore, a 




variation in this peak was consistent with the decrease in the concentration of PVA, SiO2 
in the PVA-SiO2-IONP formulation, as compared to neat PVA and PVA-SiO2 gels. This 
could also be an indication that the complex interactions among PVA, SiO2 and IONP 
have weakened certain interactions.  
The near-linear magnetization curve implied the paramagnetic property of the PVA-SiO2-
IONP microparticles, which was commonly found in FeO and Fe2O3 [64–66]. The 
formation of non-magnetite impurities could be due to the presence of oxygen and/or the 
unconfined stoichiometric and pH condition [67]. In a co-precipitation reaction, 
stoichiometry and pH are crucial to ensure the formation of Fe3O4 nanoparticles. The 
ideal ratio of Fe2+/ Fe3+ is approximately 0.5, while the optimal pH window remains 8.5-
10 [68,69]. The presence of oxygen and strong alkaline solutions could induce the 
oxidation of Fe2+ ions to Fe3+ ions, making the effective Fe2+/Fe3+ < 0.5 [67]. In the 
context of the pH effect, re-dissolutions of Fe(OH)3 and Fe(OH)2 begin at pH >11, which 
could change the composition of formed IONPs [70]. To ensure the formation of Fe3O4 
nanoparticles, excess Fe2+ ions (e.g., Fe2+: Fe3+=2:3) could be used. An alternative 
approach would be to employ argon or nitrogen to eliminate the oxygen in the system 
[71]. Nevertheless, PVA-SiO2-IONP microparticles demonstrated magnetic response and 
zero residual magnetization was produced. This suggests that these microparticles do not 
retain any magnetization after the external magnetic field is removed, which can 
potentially avoid the particle agglomeration in vivo [72]. Magnetic PVA-SiO2-IONP 
microparticles may find their application in MRI contrast enhancement and magnetic 
targeting.  
5.4.3 Drug Concentration Effect on DOX Loading 
PVA-SiO2-IONP microparticles could achieve a greater DOX loading and lower 
entrapment efficiency at a higher initial DOX concentration. This phenomenon could be 
attributed to the finite number of binding sites when the amount of microparticles was 
fixed. Moreover, the increase in loading (in percentile) was smaller than in the DOX 
concentration, indicating a longer incubation time might be necessary. The competition 




5.4.4 In vitro Release of DOX 
The effect of ionic concentration and pH on DOX elution was shown in Figure 7 A-C. At 
all loading levels, DOX release was faster in pH 5.5 phosphate buffer than in the H2O of 
the same pH, indicating the presence of ions in elution medium can accelerate the release. 
Acidic phosphate buffer rendered faster release compared with saline. As the ionic 
concentration and pH were different for the two buffers, it is challenging to claim the pH 
effect on DOX release. However, we believe that an acidic pH plays an essential role in 
DOX release. DOX is an amphoteric drug that presents predominantly in its cationic form 
[73]. It contains deprotonable phenolic groups (-OH, pKa 9.5) and a protonable amine 
group (-NH2, pKa 8.2) [74]. Yang et al. assembled a DOX-loaded delivery system using 
graphene oxide. DOX elution profile was studied at three pHs (2, 7 and 10), and the 
acidic pH environment provided the fastest and greatest release. It was hypothesized that 
the DOX interacted with the carrier through the hydrogen bonding between the -OH 
groups on the graphene sheet with the -OH and -NH2 groups in DOX. In an acidic 
environment, the protonation of amine groups accelerates the DOX release by reducing 
the number of functional groups available for hydrogen bonding [75]. Such pH-
dependent release is particularly attractive for drug delivery applications. It can 
potentially allow tumor-specific release, because the pH value in tumor tissue (pH 6.5-
6.8) is different from healthy tissue (pH 7.35-7.45) [76]. 
As shown in Figure 7 D, PVA-SiO2-IONP microparticles with a higher loading provide a 
slower DOX release. This could be explained by the increased hydrophobicity of the 
microparticles after loading. It was found that the DOX molecules could introduce π − π 
drug-drug interactions, which increased the hydrophobicity of the drug carriers [4]. As 
such, microparticles with greater DOX loading became more hydrophobic than those 
with lower loading. As a consequence, the water penetration hence drug diffusion would 
be retarded, resulting in a slower drug release [77].  
For all subgroups, an incomplete drug release was observed, which could possibly be 
explained by the entrapment of DOX in the hydrogel matrix and/or the adsorption of 
DOX to the surface of the glass vials [78,79]. The plateau phase in DOX release could be 




progresses. Future study could be conducted for an extended period of time to fully 
reveal the drug release profile. Nevertheless, the release was sustained for 7 days, and the 
release rate was adjustable by altering the DOX loading. Such release profile could be 
engineered to comply with the frequency of TACE treatments and provide a better tumor 
response due to the prolonged drug release [16].  
5.4.5 Degradation of Microparticles 
It has been hypothesized that the degradation of microbeads was contributed by the iron 
dissolution and PVA matrix disintegration (Chapter 3). This study provides additional 
quantitative data to support the hypothesis. However, we are not able to conclude the 
degradation mechanism of PVA-SiO2-IONP microbeads because the impact of silica 
dissolution on degradation is yet to be elucidated. Future studies on sample weight loss, 
thermal properties, compositional analysis of the degradation medium are required to 
understand the degradation process fully. The degradation data should also be compared 
with DOX release profile to better understand the role of carrier degradation in drug 
release. 
5.5 Conclusion 
Multifunctional microparticles were successfully prepared from poly(vinyl alcohol), 
silica and iron oxide via sol-gel synthesis, in situ co-precipitation and microfluidics. The 
size of the microparticles was tunable by adjusting the flow rate of the continuous phase 
and dispersed phase. The PVA-SiO2-IONP microparticles were able to load DOX and 
provide a controlled release for 7 days. This could be followed by a sustained but slow 
release of the rest of the payload as the degradation progresses. The release profile was 
adjustable by altering the drug loading. It was speculated that the DOX release from the 
system was co-dependent on the ionic concentration and pH of the release medium. 
Furthermore, the microparticles were subject to degradation in physiological conditions. 
Taken together, multifunctional PVA-SiO2-IONP microparticles can be potentially used 
as drug-eluting agents for locoregional therapy, such as transarterial chemoembolization 
and wound healing. Further research in the PVA-silica interaction and microparticle 
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6 Conclusion and Recommendations 
6.1 Summary and Conclusion 
The overall objectives of this thesis are to develop multifunctional drug delivery systems 
for locoregional therapy (Figure 6.1). Nano- and microparticulate systems were prepared 
using organic or inorganic biomaterials. These delivery systems were characterized in 
their composition, morphology, drug loading/release and degradation. The results 
demonstrated sustained drug release capacity and in vitro degradability. The summary of 
each delivery system is presented below. 
 
Figure 6.1 Schematic of the research work described in Chapter 3-5. 
In Chapter 3, multifunctional PVA-IONP microparticles were developed as DEBs for 
TACE treatment. The superparamagnetic IONPs were entrapped in the PVA matrix 
through in situ coprecipitation and freezing-thawing cycles. Droplet microfluidics was 
employed to fabricate microparticles. The resulting beads were in a teardrop shape with a 




functionalities relevant to the application as DEBs, including targetability, detectability, 
controlled DOX release and degradation. The highlights of this project are: 
1. Targetability. PVA-IONP microparticles were superparamagnetic and can be 
attracted by a permanent magnet. 
2. Imageability/Detectability. Microparticles were effective in producing a contrast 
enhancing effect on T2-weighted MRI images. 
3. DOX loading and release. PVA-IONP microparticles provided a DOX loading of 
0.49 ± 0.02 mg/mL. The release was in a sustained manner during the course of 
one week.  
4. Degradability. The degradation of the microbeads was in the form of iron release 
and PVA matrix disintegration.  
5. Co-localization of contrast agent with DOX. This would about a precise location 
of the carrier and drug in relevance to tumor site. 
Chapter 4 described the development of bioactive proteins and peptides delivery system 
using non-porous SiNPs. The system was first assembled using lysozyme as the model 
protein. The adsorption kinetics and isotherm were studied to reveal the loading 
mechanism. Protein release and the dissolution of SiNPs in PBS were investigated. The 
SiNPs were then loaded with N-94, the peptide derived from a tear glycoprotein, lacritin, 
that is effective in dry eye treatment. The SiNP system is attractive as a drug delivery 
formulation for treating dry eye disease. 
The highlights of this work are shown below: 
1. Protein loading is driven by chemisorption and will form a monolayer on SiNP 
surface at low protein concentration. As such, it is expected to be a maximum 
loading capacity determined by the number of binding sites and hindrance effect.  
2. SiNPs can provide a controlled release for proteins and peptides for 8 hours. 
3. The nanocarriers can protect molecular integrity and biofunctions of the peptides. 
4. SiNPs are dissolvable in PBS. The dissolution is time-dependent and results in 
reduced particle size and a porous structure.  
5. N-94 is functionally equipotent to its parent protein, lacritin. 




Chapter 5 introduced the development of PVA-SiO2-IONP system, which gives improved 
performance over the PVA-IONP microparticles in terms of increased loading capacity 
and tunable drug release. The multifunctional PVA-SiO2-IONP beads were in a tadpole 
shape and developed a paramagnetic response. SiO2 microparticles participated in the 
hydrogen bonding with PVA and improved the loading and release capacity of the 
delivery system. These microparticles are attractive as DEBs for locoregional treatment 
of diseases. The highlights of this work are listed below: 
1. The size of the microparticle could be tuned by varying the flow rates of the 
continuous and dispersed phase. 
2. PVA-SiO2-IONP microparticles rendered a 61.2% increase in DOX loading 
capacity compared with the original system. 
3. PVA-SiO2-IONP microparticles can provide a controlled release of DOX for 7 
days. The release profile is tunable by varying the drug loading. 
4. DOX release is dependent on the pH and ionic concentration of the release media. 
A more acidic pH and higher ion concentration would contribute to a faster and 
greater drug release. 
6.2 Significance of Research 
This thesis explored the development of nanoscopic and microscopic drug delivery 
systems. In Chapter 3 and Chapter 5, chemical (e.g., coprecipitation and sol-gel process) 
and physical routes (e.g., freezing-thawing cycling) were employed to prepare 
multifunctional drug carriers. Material processing techniques such as droplet microfluidic 
demonstrated efficiency and stability in producing hydrogel microparticles. The resulting 
particles exhibited the integration of several desirable properties, including targetability, 
visibility/detectability, co-localization of contrast agent with drug, sustained drug release 
and degradation. The robust and scalable microfluidic fabrication of microparticles would 
aid the success of clinical translation. The physical crosslinking method allows the 
stabilization of the hydrogel without using toxic crosslinkers, which would make the 
resulting system advantageous for in vivo applications. The resulting multifunctional 
delivery platform holds the promise to address the limitations of current DEBs, which 




In Chapter 4, a simple drug nanocarrier composed of SiNPs was developed using Stöber 
synthesis. The protein adsorption kinetics and isotherms were studied to reveal the 
loading mechanism. The adsorption pattern is helpful in determining, altering the loading 
and regulating the protein release. The SiNPs are effective in protecting molecular 
integrity and biofunction of protein therapeutics during release. The SiNP-protein system 
is a proof-of-concept design towards many applications for ocular drug delivery.  
In summary, my Ph.D. work involved significant research work in the design, synthesis, 
and processing of multifunctional materials for drug delivery applications. The choice of 
materials and fabrication techniques would guide future work in developing novel 
delivery systems. The delivery formulations we developed could be used as drug carriers 
alone. The primary application would be in TACE-HCC treatment. Other potential 
applications include TACE therapy for colorectal liver metastases and hyperthermia 
treatment for brain tumor. The application could be further expanded if they were 
combined with other delivery platforms, such as microfibers, scaffolds and contact lens to 
serve as drug-eluting medical devices.  
6.3 Future Studies 
Based on the length scale of the delivery system we designed, this thesis could be 
aggregated into two main projects. Chapter 3 and Chapter 5 described the development of 
multifunctional ‘nano-on-micro’ microparticles. Chapter 4 involved work on the 
development of silica-based nanocarriers for protein delivery. Future studies will be 
discussed for Chapter 3 and 5 together, and separately for Chapter 4, due to the similarity 
of the work.  
Development of multifunctional hydrogel microparticles (Chapter 3 and Chapter 5) 
The co-flow or three-dimensional (3D) flow-focusing microcapillary devices should be 
explored to produce the microparticles [1]. This architecture would allow a better sealing 
than quasi-2D planar devices, which is expected to secure the driving force (i.e., the 




robustly delivering the fluids [2]. In addition, a 3D geometry would circumvent the 
unstable breakup of droplets, as the fluids do not contact the walls [3].  
To examine the targetability of the multifunctional ‘nano-on-micro’ microparticles, MR 
steering could be tested in bifurcated fluidic tubing using a clinical MRI scanner [4]. The 
distribution of particles should be recorded to evaluate the spatial control of system. 
Steering ratio and mass loss can be quantified to assess the sensitivity and reliability of 
this approach.  
In the degradation study, additional quantitative and qualitative experiments could be 
conducted. Size exclusion chromatography (SEC) can be employed to examine the 
microbeads. Changes in molecular weight and molecular weight distribution could 
indicate the degradation of PVA [5]. Differential scanning calorimetry (DSC) could be 
performed to monitor the changes in glass transition temperature during the degradation. 
Dynamic light scattering (DLS) can be utilized to measure the size reduction caused by 
the disintegration of the matrix. Moreover, the degradation could be quantified 
gravimetrically.  
Future work should also be dedicated to revealing the biocompatibility and efficacy of 
the drug eluting microparticles. For biocompatibility study, normal cells (e.g., epithelial 
cells) could be incubated with drug-free microparticles. Cell apoptosis should be 
analyzed by flow cytometry. To study the efficacy of the delivery system, cancer cells 
(e.g., HepG2 cells) could be treated with drug-loaded particles. The antitumor effect of 
the system against HepG2 cells could be evaluated using a methyl thiazolyl tetrazolium 
(MTT) assay. Morphological changes of cells in response to the treatments will be 
microscopically examined to reveal the apoptosis pathway [6]. 
To explore the full application spectrum of our multifunctional delivery systems, studies 
on drug release and heating effect could be conducted with the presence of an alternating 
magnetic field (AMF). This would allow the assessment of their clinical applicability in 





Development of silica nanocarriers for bioactive protein delivery (Chapter 4) 
This study demonstrated the feasibility of using SiNPs as protein carriers. Future work 
should focus on improving the loading capacity and demonstrating the superiority of the 
drug delivery systems over free drugs. In detail, porous SiNPs could be synthesized to 
improve the loading capacity. Alternatively, non-porous SiNPs could be functionalized to 
introduce more surface binding sites. A cell study could be performed to examine the 
effectiveness of delivery systems. Stressed corneal cells could be treated with free 
bioactive proteins and SiNP-protein systems separately. A comparative study on cell 
viability and metabolism should be performed. 
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Appendix A: PVA-IONP microbeads size measurement 
 
Equivalent spherical diameter is calculated using the following equation:  
𝑑 = 2√𝐴/𝜋 







Appendix B: Preparation of pH 5.5 phosphate buffer 
Solution I: dissolve 13.61 g of potassium dihydrogen phosphate (KH2PO4) in distilled 
water and dilute to 1000 mL. 
Solution II: Dissolve 35.81 g of disodium hydrogen phosphate (Na2HPO4) in distilled 
water and dilute to 1000 mL.  




































































Table S2 Fitting parameters for Freundlich, Langmuir and Redlich-Peterson isotherms. 
 
Figure S1 Comparison between the measured and modelled equilibrium isotherm profile.  
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